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Abstract 
Isoprenoids (or terpenes) are a large class of compounds with great physiological 
importance in all kingdoms of life. The research in this work explored the mechanism and 
inhibition of several enzymes in two important pathways for isoprenoid biosynthesis.  
The first pair of enzyme are IspG and IspH, which constitute the last two steps in the 
MEP/DOXP (or non-mevalonate) pathway, which some bacteria, protozoa and plants rely on to 
produce the basic building blocks of isoprenoids, isopentenyl pyrophosphate (IPP) and 
dimethylallyl pyrophosphate (DMAPP). IspG and IspH are both 4Fe-4S cluster-containing 
proteins with a unique iron whose ligand is not a cysteine residue. Continuous-wave and pulsed 
electron paramagnetic resonance (EPR) experiments, with the help of isotope-labeled substrates, 
revealed the electronic structures of reaction intermediates and inhibitors bound to the iron-
sulfur clusters. Diverse binding modes of ligands to the clusters were discovered. In addition to 
IspG and IspH, another 4Fe-4S protein, NadA (in a biosynthetic pathway to NAD) was also 
mechanistically studied. 
The second pair of enzymes are FPPS and SQS, the enzymes responsible for the first two 
steps of the biosynthetic pathway of sterols in animals, bacteria and protozoa. We focused on the 
inhibition and structure aspects of the FPPS and SQS enzymes of the protozoan pathogen 
Trypanosoma cruzi. For a series of bisphosphonate inhibitors, structure-activity relationship was 
explored, as well as their cell-killing capability.   
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Chapter 1. Introduction 
1.1. Isoprenoids and Isoprenoid Biosynthesis 
Isoprenoids, also known as terpenoids, are a large class of compounds present in all 
kingdoms of life. To name a few of them: Retinol is a form of vitamin A essential for vision; 
staphyloxanthin is a pigment giving Staphylococcus aureus its characteristic gold color as well as 
an antioxidant against host defense; ergosterol is an essential component of the cell membrane of 
several parasitic protozoa; and cholesterol, probably the best-known isoprenoid, acts as a 
structural component of animal cell membranes, as well as a precursor to certain hormones. 
Overall, there are over 65,000 known compounds belonging to this category (1), diverse in 
chemical structures and physiological functions.  
It is therefore natural that living organisms have a myriad of biosynthetic pathways leading 
towards isoprenoids. However, what remains invariant for the isoprenoids are their common 
basic building blocks, two five-carbon pyrophosphates: isopentenyl pyrophosphate (IPP) and 
dimethylallyl pyrophosphate (DMAPP) (2), which provide them with the basic isoprene unit. 
Organisms carry out catabolism from various carbon sources, which are converted to the basic C-
5 building blocks, and the C-5 building blocks are in turn converted to different end products. 
Therefore, IPP and DMAPP form the point where many biosynthetic pathways converge and 
must pass through, as shown in Figure 1.1.  
With the overarching goal being the development of new inhibitors against the enzymes in 
these pathways, the main targets in this research have been set at two pairs of enzymes 
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immediately upstream and downstream of the IPP/DMAPP “chokepoint”, as highlighted in 
Figure 1.1.  
The first pair of enzymes targeted, (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate 
(HMBPP) synthase (IspG, also known as GcpE) and HMBPP reductase (IspH or LytB), catalyze 
the last two steps of the 2-C-methyl-D-erythritol 4-phosphate/1-deoxy-D-xylulose 5-phosphate 
(MEP, DOXP, or non-mevalonate) pathway that converts metabolites from catabolism to IPP and 
DMAPP in certain organisms. Both enzymes contain 4Fe-4S clusters that are essential for the 
2H+/2e- reduction of their respective substrates. Both clusters have three iron atoms attached to 
the protein via a cysteine ligand, while the “unique” fourth iron has a non-cysteine ligand. We 
elucidated the mechanisms of both enzymes by trapping reaction intermediates and probing the 
electronic structure of these intermediates with continuous-wave EPR (electron paramagnetic 
resonance) and pulsed EPR spectroscopies. In addition, we found inhibitors for the enzymes, 
some of which are effective against both IspG and IspH. 
The second pair of enzymes, farnesyl diphosphate synthase (FPPS, also called IspA) and 
squalene synthase (SQS), catalyze the first two steps in the pathways from IPP and DMAPP to 
various sterols, e.g. cholesterol in animals and ergosterol in fungi and protozoa. This research 
investigated the inhibition of both enzymes by a series of lipophilic bisphosphonates, some of 
which are also shown to inhibit the growth of the protozoan Trypanosoma cruzi (the cause of the 
tropical Chagas disease) in its pathologically relevant phase of life cycle.  
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1.2. The MEP Pathway, IspG and IspH 
In different organisms, IPP and DMAPP are synthesized in two distinct, non-homologous 
pathways – the “classical” mevalonate pathway (also dubbed MVA pathway or HMG-CoA 
pathway) discovered in 1950s, and the MEP/non-mevalonate pathway (3) discovered more 
recently (1990s). The distribution of the two pathways in various organisms is complex (4), but to 
summarize crudely, the mevalonate pathway is more prevalent in archaea, yeasts and animals, 
the presence of the non-mevalonate pathway is biased towards bacteria and the apicomplexa 
group of parasitic protists, and plants tend have both pathways.  
Humans rely solely on the mevalonate pathway for the synthesis of IPP and DMAPP, while 
many bacterial and protozoan pathogens produce the essential building blocks IPP and DMAPP 
exclusively through the non-mevalonate pathway. Such a pathway distribution presents an 
opportunity for development of anti-infective drugs with the MEP pathway as an antibiotic 
target. As shown in Figure 1.2, the MEP pathway utilizes G-3-P (glyceraldehyde-3-phosphate) 
and pyruvate as starting material to make IPP and DMAPP. The enzyme catalyzing the second 
(and the first committed) step of the pathway, 1-deoxy-D-xylulose-5-phosphate reductoisomerase 
(Dxr or IspC), has been under active development (5) as a target against E. coli, Plasmodium spp., 
and Mycobacterium tuberculosis. 
In addition to their potential as drug targets, the last two enzymes of the MEP pathway, 
IspG and IspH, are also of interest to bioinorganic chemists for the mysteries in their mechanisms 
of action involving cubane type 4Fe-4S clusters. Unlike ferredoxin type of 4Fe-4S clusters, where 
each of the four Fe atoms attaches to the protein via coordination to a deprotonated cysteine thiol 
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group, their 4Fe-4S clusters have only three cysteine-liganded Fe atoms while the fourth unique 
Fe binds to a different ligand. 
Both IspG and IspH catalyze 2e-/2H+ reductions of their respective substrates, 2-C-methyl-
D-erythritol 2,4-cyclopyrophosphate (MEcPP) and HMBPP. For each enzyme, researchers have 
proposed multiple mechanisms of action: at least 4 for IspG (6–9) and 6 for IspH (10–15), with 
carbocation, carbanion, epoxide, radical and ferraoxetane intermediates. 
Therefore, the structures and ligand binding modes of IspG and IspH in complexes with 
substrates, reaction intermediates or products are of great mechanistic interest, as will be 
discussed in Chapters 2 and 3 of this dissertation, respectively. 
Mechanistic insights have also facilitated ideas of inhibitor design of IspG and IspH. Many 
chemical species have been screened and potent inhibitors found. In Chapter 4 it will be shown 
that several of these inhibitors exhibit diverse binding modes, with the focus on IspH inhibitors. 
 
1.3. 4Fe-4S Protein Beyond IspG/H: Quinolinate Synthase 
Our interest on 4Fe-4S proteins with the unique fourth iron extends beyond the scope of 
isoprenoid biosynthesis. One such enzyme of interest is quinolinate synthase (NadA). Relatively 
recently confirmed as a 4Fe-4S cluster-containing protein (16,17), NadA has a striking structural 
similarity with IspH – both have a novel trefoil fold with the 3 iron-sulfur cluster ligand cysteine 
located on the loops between the three “petals”, and the iron-sulfur cluster at the center, as 
revealed by X-ray crystallography with or without the complete 4Fe-4S center present (18–21).  
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Quinolinate synthase belongs to one of the two de novo biosynthetic pathways of NAD+ 
synthesis (22), shown in Figure 1.3. Depending on the organism, de novo NAD+ biosynthesis is 
conducted with either tryptophan (also called the kynurenine pathway) or aspartate as the 
starting material. Characteristically, a new pyridine ring is synthesized through the de novo 
pathways. In addition, various organisms also synthase NAD+ from salvaged pyridine bases, 
nicotinic acid or nicotinamide, via the salvage pathways. A few pathogenic microorganisms, such 
as Helicobacter pylori (23) and Mycobacterium leprae (24), lack the salvage pathway and rely solely 
on the de novo aspartate pathway. With most animals (including human) utilizing the salvage and 
tryptophan pathways, the aspartate pathway makes a good antibacterial target.  
NadA catalyzes the formation of the pyridine ring in the end product. It cyclizes one 
iminoaspartate (IA) and one dihydroxyacetone phosphate (DHAP) to form a pyridine-2,3-
dicarboxylate, or quinolinate (QA). The enzymatic reaction involves a relatively complex set of 
steps: the loss of one phosphate group, a triose phosphate isomerase-like aldehyde-ketone 
isomerization, Schiff base formation and loss of water. There have been speculations of NadA 
mechanism (20,21,25,26), but most studies lack direct evidence, e.g. the presence of reaction 
intermediates. The details of the mechanism remains largely unclear, and is of particular interest 
from an enzymology point of view. Chapter 5 will present some preliminary results of a study 
on NadA mechanism. 
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1.4. Prenyl-Transferases FPPS and SQS 
The final focus of this research is the initial steps from IPP and DMAPP to many important 
isoprenoids. As shown in Figure 1.4, farnesyl pyrophosphate, a C-15 isoprenoid, is the first-step 
precursor to many families of complex terpenes, such as carotenoids and ubiquinone (27). It is 
also a molecule utilized in the post-translational modification of proteins (28) such as Ras, 
important in signaling pathways. In many biosynthetic pathways, the next step condenses two 
farnesyl pyrophosphate molecules into the C-30 squalene, the precursor that will cyclize to form 
steroids such as cholesterol (29), ergosterol (30) and hopanoids (31).  
The enzymes responsible for the first step is farnesyl pyrophosphate synthase (FPPS).  FPPS 
acts as head-to-tail prenyl transferase (Figure 1.5). The allylic substrate (DMAPP) loses 
pyrophosphate and forms a carbocation, which in turn is attacked by the double bond of the 
homoallylic substrate (IPP), forming a C-10 allylic pyrophosphate, geranyl pyrophosphate (GPP). 
GPP is attacked by a second IPP molecule and forms the C-15 product FPP. FPPS exists in the 
toxoplasmosis pathogen Toxoplasma gondii (32), the Trypanosoma pathogens Trypanosoma cruzi (33) 
and T. brucei (34). In the malaria parasite Plasmodium species, it also catalyzes further 
condensation with IPP to form the C-20 product, geranylgeranyl pyrophosphate (GGPP) (35), 
making the enzyme a dual-functional FPP/GGPP synthase. It is also discovered that FPPS 
inhibition leads to γδ T cell activation, possibly due to the accumulation of IPP, a 
“phosphoantigen” (36). These factors combined, it is clear that FPPS is of interest in the context 
of both anti-infective and anti-cancer drug development. 
Squalene synthase (SQS), like its homolog dehydrosqualene synthase (CrtM), is a head-to-
head prenyl transferase (Figure 1.6). Both enzymes condense two FPP molecules initially into the 
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C-30 intermediate presqualene pyrophosphate (PSPP). PSPP then undergo loss of 
pyrophosphate, ring opening and NADPH-dependent reduction to form squalene – the first 
committed step in sterol biosynthesis. By contrast, the CrtM reaction proceeds without reduction, 
producing dehydrosqualene. It was previously shown that a CrtM inhibitor blocked the 
formation of the S. aureus virulence factor staphyloxanthin (37). Many inhibitors are observed to 
have SQS/CrtM dual inhibitory activity (38). Given the importance of sterols, it is of interest to 
develop SQS inhibitors not only as antibiotics, but also as cholesterol-lowering alternatives to 
statins (39). 
In Chapter 6 inhibitory studies of FPPS and SQS will be presented, with focuses on SQS. 
An important family of inhibitors are lipophilic bisphosphonates which showed SQS inhibition 
as well as T. cruzi cell-killing activity. We performed an experimental structure-activity 
relationship study of lipophilic bisphosphonates with varying length of the aliphatic side chain. 
  
1.5. Overall Research Strategies 
The two main themes of this dissertation are: (i) Obtaining mechanistic understanding of 
the enzymes of interest, especially for the iron-sulfur proteins; (ii) rationally designing inhibitors 
of the enzymes, all of interest as drug targets. 
A key feature of these iron-sulfur proteins is that they are paramagnetic in certain 
functionally relevant redox states. As will be discussed later, IspH and IspG catalyze redox 
reactions that involve [Fe4S4]1+ and/or [Fe4S4]3+ states. It has also been shown that NadA, though 
typically considered at the diamagnetic [Fe4S4]2+ state, is also active under reductive conditions 
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(26). Given that intact 4Fe-4S clusters are essential for the function of the enzymes, EPR 
spectroscopy (40), which probes the electronic structure around of paramagnetic species, would 
provide highly informative data about the mechanism, especially when we can freeze-trap 
reaction intermediates along the reaction coordinate.  
However, continuous-wave EPR is limited in resolution. With pulsed EPR techniques (41), 
such as electron nuclear double resonance (ENDOR), electron spin echo envelope modulation 
(ESEEM) and two-dimensional hyperfine sublevel correlation (HYSCORE), superior resolution 
can be attained. Particularly, when ligands with non-zero spin nucleus are present in the vicinity 
of the paramagnetic iron-sulfur cluster, hyperfine and quadrupole (when the nucleus has spin I 
≥ 1/2) couplings can be determined through simulation of spectrum. In this light, ligands with 
non-zero spin nuclei, including natural abundance 1H, and 14N, as well as enriched 2H, 13C, 15N, 
and 17O-labeled proteins and/or ligands, will provide a valuable mechanistic probe. 
Molecular biology methods, for example site-directed mutagenesis, also provide important 
tools for gaining mechanistic insight. Bioinformatic tools, such as conservation scoring, thus 
provide guidance for mutagenesis experiments. 
For inhibitors and drug discovery, kinetic assays are the most important routines on the lab 
bench. Various analytical methods, including spectrophotometry, scintillation counting and 
HPLC, are utilized.  
Finally, X-ray crystallography provides most direct evidence of structural features of 
enzyme-ligand complexes.   
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1.6. Tables and Figures 
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Figure 1.1: A simplified illustration of pathways of isoprenoid biosynthesis, highlighting the 
enzymes of interest in this study. 
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Figure 1.2: The MEP/DOXP pathway. Adapted with permission from Ref. (2). Copyright 2004, 
Springer. 
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Figure 1.3: Two different de novo pathways of NAD+ biosynthesis. (A) The aspartate pathway, 
genes in E. coli naming; (B) The tryptophan (kynurenine) pathway, genes in S. cerevisiae naming. 
Adapted with permission from Ref. (22). Copyright 2009, American Society for Microbiology.
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Figure 1.4: FPPS and downstream pathways towards various products, including SQS and 
synthesis of sterols. Adapted from Ref. (42) under Creative Commons Attribution 4.0 license. 
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Figure 1.5: Mechanism of FPPS, showing the head-to-tail condensation. Some FPPS can condense 
another IPP molecule to FPPS, functioning as GGPPS. 
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Figure 1.6: Mechanisms of SQS and CrtM. Adapted with permission from F-Y Lin et al (43). 
Copyright 2012, American Chemical Society. 
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Chapter 2. Mechanism of Action of 4Fe-4S Protein IspG 
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2.2. Introduction 
As discussed in Section 1.2, in the early days of IspG research, the mechanism of IspG had 
been elusive, with a number of proposals without enough direct evidence of observation of the 
proposed intermediate species. In 2007, it was observed that while it was difficult to fully reduce 
Thermus thermophilus IspG cluster with dithionite, in a steady state condition with both dithionite 
and the substrate MEcPP, a species with intense EPR signal similar to a HiPIP (high-potential iron 
protein) 4Fe-4S cluster become observable and then disappeared after a duration of minutes (44). 
This observation suggested that a paramagnetic reaction intermediate, hereafter dubbed “X”, is 
present. Effort was therefore made to elucidate the structure of “X”, with isotope-labeled 
substrates and pulsed EPR spectroscopy. 
 
2.3. Results and Discussion 
2.3.1. CW-EPR observation of reaction intermediate “X” 
The IspG reaction substrate MEcPP and product HMBPP, shown in Figure 2.1, form 
paramagnetic complexes in the presence of dithionite. The intermediate “X” is clearly observable 
by continuous-wave (CW) EPR upon MEcPP binding and reduction by dithionite (Figure 2.2B), 
with g tensor gi = [2.092, 2.018, 1.999]. It converts to the HMBPP-IspG complex after 45 minutes of 
incubation (Figure 2.2D, E), with gi = [2.092, 2.010, 1,976]. Since Nyland et al (45) reported that 
HMPPP-epoxide also converts to HMBPP catalyzed by IspG, an attempt to produce the 
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intermediate “X” with HMBPP-epoxide was also made, and an essentially identical EPR 
spectrum was recorded (Figure 2.2C).  
2.3.2. Fermentation and chemical synthesis of MEcPP 
Because of the difficulties of chemical synthesis of MEcPP, “fermentation engineering” 
experiments to produce MEcPP biosynthetically were performed, according to modified 
previously described protocols (46) using Corynebacterium ammoniagenes cells. With this method, 
production of several isotope-labeled MEcPP was also possible. For [u-2H]-MEcPP, C. 
ammoniagenes cells were acclimatized with increasing D2O percentage in growth media, and 
uniformly-deuterated MEcPP is produced in 100% D2O growth media with [u-2H7]-D-glucose as 
carbon source. For [u-13C5]-MEcPP, cells are fed with [u-13C6]-D-glucose. For specifically 13C-
labeled MEcPP, various 13C-labeled glucose was fed to the bacteria to produce MEcPP labeled 
according to knowledge of glycolysis and MEP pathways (2), but enrichment was reduced. In the 
end only [2-13C]-D-glucose produced MEcPP with 30% enriched at both C-2 and C-3 positions 
(numbering according to Figure 2.1). In addition, [1,3,4-13C3]-MEcPP was gifted to us by authors 
who reported methods of producing labeled-MEcPP with purified enzymes (47). 
For 17O and 2H at specific positions, HMBPP-epoxides were chemically synthesized by Dr. 
Ke Wang. 
2.3.3. ENDOR and HYSCORE spectra and assignment 
The first important clue of the structure of “X” comes from the hyperfine interaction of 13C-
labeled MEcPPs with the iron-sulfur cluster, as shown in the HYSCORE spectra of them in Figure 
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2.3. In the HYSCORE (48) spectra of an I = ½ nucleus, a pair of peaks appear on the spectrum, 
centered at the Larmor frequency νL of the nucleus, and separated by the hyperfine coupling A.  
With “X” formed from [U-13C]-MEcPP, we can observe one pair of peaks in the (-, +) 
quadrant representing a large hyperfine coupling, which can be simulated with Aii = [14.5, 12.0, 
26.5] MHz, Aiso = 17.7 MHz. Next, there is a pair of peaks representing smaller hyperfine coupling, 
with simulation Aii = [1.8, 2.0, 5.1] MHz, Aiso = 3.0 MHz. There might be additional unresolved 
small hyperfine peaks around the 13C Larmor frequency (~ 3.6 MHz), overlapping with double 
quantum transition signal from 14N in the protein backbone. 
The Aiso = 17.7 MHz peak is present with [U-13C5] and [1,3,4-13C3] substrates, but not present 
in [2,3-13C2] substrate, and therefore can be unequivocally assigned to the quaternary carbon, C2, 
of MEcPP. The Aiso = 3.0 MHz signal, present in all three 13C labeled samples, can then be assigned 
to C3. 
The HYSCORE spectrum from 17O labeled HMBPP-epoxide also exhibits signal at the (-, +) 
quadrant, with A ~ 8 MHz, as shown in Figure 2.4. Due to low isotopic enrichment and complex 
broadening schemes of an I = 5/2 nucleus, it is difficult to quantitatively simulate the 17O 
HYSCORE spectrum. But qualitatively, this large hyperfine interaction indicates high electron 
spin density on the 17O atom.  
Next, we prepared “X” from deuterated MEcPP or HMBPP-epoxide, and utilized pulsed 
ENDOR technique (49) to explore 1H and 2H hyperfine coupling at high resolution. With natural 
abundance MEcPP, ENDOR of “X” shows a 1H signal with Aii = [14, 11, 11] MHz, Aiso ~ 12 MHz 
(Figure 2.5A). This proton does not exchange with deuterated solvent (Figure 2.5B), while its 
signal disappears when “X” is prepared with uniformly deuterated MEcPP (Figure 2.5C). To 
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specifically assign this signal, deuterated HMBPP-epoxide were utilized to prepare “X” for 
ENDOR spectroscopy (Figure 2.6). Given that the gyromagnetic ratio of 1H is about 7 times that 
of 2H, one can expect this signal to appear in 2H spectrum with A ~ 1.7 MHz. As a result, this 
signal corresponds to HMBPP-epoxide deuterated at the 2’-methyl group, while samples 
deuterated at other positions showed weaker hyperfine coupling, overlapping with each other 
and could explain the central envelope of the [u-1H]-MEcPP and [u-2H]-MEcPP spectra.  
2.3.4. Structure of “X” and the ferraoxetane mechanism  
Taken the above spectroscopic results together, we conclude that the most plausible 
structure of the reaction intermediate is a ferraoxetane, the possible pathway to it is shown in 
Figure 2.7, and the ferraoxetane structure shown in Figure 2.7C. This structure of “X” is favored 
for the following reasons: (i) The large 13C hyperfine coupling from C2 has both large isotropic 
and anisotropic terms, Aii = [14.5, 12.0, 26.5], indicating both large Fermi contact interaction 
(isotropic term) and spatial proximity (anisotropic term), hence the possibility of a direct Fe-C 
bond. The observed 13C hyperfine coupling in “X” is also close to that seen for 13CO directly 
bonded to one of the irons in the H cluster in the Hox-CO state of an [FeFe] hydrogenase, for which 
Aii(13CO) = [19.2, 16.6, 15.6] MHz (50). (ii) The methyl signal, with Aii(1H) = [14, 11, 11] MHz, has a 
relatively large isotropic term indicating some significant Fermi contact interaction, but the small 
anisotropy indicates long spatial distance. With the structure of “X” in Figure 2.7C, the methyl 
group is spatially far away from the paramagnetic center, while the proton is 3 bonds away from 
the unique fourth iron, and hyperconjugation could presumably enhance the Fermi contact 
interaction. The large spin density on one of the methyl hydrogens has also been corroborated by 
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a DFT calculation (51). (iii) The large 17O hyperfine coupling, A ~ 8 MHz indicates direct Fe-O 
interaction, similar to that previously obtained with aconitase (52,53), A ~ 8 - 15 MHz.  
 
2.4. Conclusions 
In a nutshell, we have been able to freeze-trap the paramagnetic reaction intermediates and 
elucidate the structural features with CW and pulsed EPR spectroscopies. With the help of 
biosynthesized and chemically synthesized isotope-labeled substrates, we were able to assign the 
spectroscopic features to atoms in the reaction intermediates. The results strongly supported an 
organometallic ferraoxetane species with direct Fe-C bonding – an unusual phenomenon of great 
general interest – as an enzymatic reaction intermediate. With these results, we were able to 
establish a preliminary picture of mechanism of action for IspG involving a ferraoxetane, while 
other chemical steps before and after this intermediate might be understood by further 
spectroscopy, mutagenesis, inhibition and crystallography studies. 
 
2.5. Materials and Methods 
2.5.1. T. thermophilus IspG protein expression and purification 
Plasmids with T. themophilus gene construct was transformed into BL-21(DE3) cells 
(Invitrogen). Cells were grown in LB media supplemented with 150 mg/L ampicillin at 37 °C with 
225 rpm shaking. When OD600 reached ~ 0.3, medium was supplied with 0.1 g/L L-cysteine and 
0.1 mM FeCl3. When the OD600 reached ~ 0.7 – 0.8. Cells were then induced with 1 mM IPTG. 
Incubation then continued at 25 °C for 8 – 16 h with the incubator shaking at a reduced speed of 
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80 rpm. Cells were then harvested by centrifugation (9000 rpm, 10 min, 4 °C), flash frozen at -80 
°C, and kept frozen until further use.  
Purification was then carried out in a Coy anaerobic chamber in a cold room set at 4 ∘C. 
Care was taken to ensure all actions were performed when the oxygen content is less than 2 ppm 
in the anaerobic chamber. All the buffers used are also degassed on a Schlenk line before being 
transferred into the anaerobic chamber for use. Cell pellets were re-suspended in 15 - 30 mL buffer 
containing 50 mM Tris ̇⋅HCl, pH 8.0 and 150 mM NaCl. 2 μL of benzonase nuclease solution (EMD 
chemicals), ~ 2 mg of phenylmethanesulfonyl floride (PMSF, Aldrich), and 5 mM TCEP were 
added to the mixture before cells were lysed by sonication (Fisher Scientific Sonic Dismembrator 
Model 500) with 5 second pulse totaling 1 – 2 minute at 50% power. The suspension is then 
carefully sealed with 3M vinyl tape in a 50 mL centrifugation tube and centrifuged at 4 °C for 15 
min (outside the anaerobic chamber). The supernatant was applied to a HisPur Ni-NTA spin 
column (Pierce) equilibrated with a pH 8.0 buffer containing 50 mM Tris · HCl, 10 mM imidazole 
and 150 mM NaCl. After washing with 8 mL of the same loading buffer 3 times (by adding the 
buffer onto the column and centrifuging at 600×g for 2 minutes), protein was eluted with the same 
buffer plus 250 mM imidazole. Dark-brown fractions were collected, pooled, concentrated with 
a VivaSpin 20 centrifugal concentrator (GE Healthcare) and then desalted with a PD-10 column 
(GE Healthcare), to remove imidazole. The protein is stored at 4∘C until use. 
2.5.2. Biosynthesis for MEcPP 
MEcPP was produced by growing of Corynebacterium ammoniagenes cells on glucose under 
oxidative stress conditions. C. ammoniagenes (ATCC 6872) was cultured aerobically in a medium 
containing peptone (10 g/L), yeast extract (3 g/L), NaCl (5 g/L). Cells are incubated at 30 °C with 
 22 
shaking at 225 rpm. When the cells reached late log phase of growth (OD600 ∼ 1.4), the medium 
was supplemented with benzyl viologen to a final concentration of 50 mg/L, and 0.5 – 4.0 g/L 
glucose was added. Growth was allowed to continue for 18 h, and the cells were then harvested 
by centrifugation.  
The cell pellets (from 1 L growth media) were extracted with 7:3 (v/v) ethanol:water three 
times, by stirring in a flask at 4 ∘C with 40 mL of solvent each time. After rotary evaporation at 
60∘C to remove the solvent, the crude extract was dissolved in 30 mL H2O, loaded onto a 25 mL 
QAE-Sephadex A-25 (GE Healthcare) anion exchange column pre-equilibrated with 0.05 M 
ammonium acetate buffer (pH ~ 7). The column was washed with approximately 100 mL of the 
same buffer, then eluted with a linear gradient of 0.3–1.5 M NH4OAc, with a total volume of 100 
mL of eluents. The desired product eluted at approximately 0.8 M NH4OAc. The fractions were 
pooled and lyophilized, and MEcPP detected by using a GcpE activity assay and 31P NMR 
spectroscopy. The MEcPP-containing fractions were further purified by cellulose flash 
chromatography, with acetonitrile: isopropyl alcohol: 1% NH4HCO3 (in H2O) of ratios of 4:2:1 
and later 1:2:1 as eluents. The 1:2:1 solvent fractions were pooled and lyophilized. 
2.5.3. Biosynthesis of isotope-labeled MEcPP 
[u-13C5]-MEcPP is obtained by using the method above while feeding the cells with 1.0 g/L 
[u-13C6] D-glucose before adding benzyl viologen. Isotope incorporation was close to 100%, as 
determined by 13C NMR. 13C NMR (126 MHz, D2O) δ: 16.63, 16.30 (d); 65.72, 65.77, 66.06, 66.11 
(doublet of doublets); 66.98, 67.14, 67.31 (t); 68.25, 68.44, 68.60, 68.76, 68.95 (q); 83.55, 83.87, 84.22, 
84.55 (q). 31P NMR (202 MHz, D2O) δ: −13.89, −14.00 (d); −9.95, −9.85 (d). 
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MEcPP with ∼30% overall 13C labeling at C2 and/or C3 was prepared using the same 
protocol. 0.5 g/L D-glucose were added. After another 18 hours of incubation, MEcPP was 
extracted and purified as described above. The overall 13C-enrichment was ∼30% (13C0, 65.4%; 
13C1, 29.4%; 13C2, 5.2%), as determined by mass spectrometry. The sample is therefore 
essentially a mixture of [2-13C] and [3-13C]-MEcPP, but for simplicity is referred to in as [2,3-13C]-
MEcPP in this chapter. 
For the biosynthesis of [u-2H]-MEcPP, C. ammoniagenes was first “acclimatized” to growth 
in D2O. 5 mL aliquots of peptone/yeast extract/NaCl media were made, with varying H2O/D2O 
contents. Cells were first cultured in 100% H2O media, then when the OD600 reached ∼0.8, 50 μL 
of the suspension was transferred to a medium with 25%:75% D2O:H2O. Cells were then cultured 
sequentially in 50%, 75% and 100% D2O-containing media. For [u-2H]-MEcPP production, we 
used 1 L of medium with 100% D2O, cells were grown to an OD600 ∼ 1.4, 50 mg/L benzyl viologen 
and 1 mg/L [u-2H7]-D-glucose were added, and after 18 hours incubation, cells were harvested 
and MEcPP extracted as described above. 
2.5.4. EPR sample preparation 
In general, the protein sample was usually exchanged to 20%-40% glycerol containing 
buffers before being used for making EPR samples. Samples are usually prepared in a Coy 
anaerobic chamber at room temperature, with oxygen < 2 ppm during operation. For most 
samples, the protein solution was reduced with 5-20 mM sodium dithionite before any ligand(s) 
was added. The sample was injected into an 4.0 mm outer diameter EPR tube (3.8 mm for X-band 
ENDOR experiments and 1.6 mm for Q-band experiments, from Wilmad LabGlass) with a 
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syringe and a 18 cm stainless steel needle, incubated for the required amount of time, and frozen 
in liquid nitrogen before spectroscopy experiments. 
To prepare one-electron reduced AaIspH EPR samples, 0.5 – 1 mL reconstituted protein 
solution (2.5 mM) was first incubated with 20 – 25 mM sodium dithionite for 30 minutes in the 
anaerobic chamber at 4∘C. After reduction, the solution was desalted with a PD-10 column to 
remove excess sodium dithionite. The desalted eluent was mixed (1:1 volume) with a degassed 
40% glycerol solution, and then concentrated with an Amicon centrifugal filter (10,000 molecular 
weight cutoff) so that the final volume approximated the initial volume. The protein solution was 
aliquoted according to the sample volume required by EPR spectroscopy (typically 100 – 200 μL 
for X-band, 10 – 15 μL for Q-band). Ligand solution was then added to an aliquot of the protein 
solution to a typical final concentration of 10 – 15 mM, swiftly mixed and injected into the X-band 
and/or Q-band EPR tubes which were then frozen in liquid nitrogen. Typically the time from 
ligand addition to sample freezing should take less than 30 seconds. 
2.5.5. CW-EPR spectroscopy 
All CW-EPR experiments were performed on a Varian E-line 122 X-band spectrometer with 
an Air Products helium cryostat. Typical data acquisition parameters were: microwave frequency 
9.04 - 9.25 GHz; field center 3250 gauss or 2500 gauss, with field sweep 1600 gauss or 5000 gauss; 
modulation frequency 100 kHz; modulation amplitude 5 gauss; time constant 32 milliseconds; 
gain 1000 to 20000; temperature 8 - 20 K. Usually each field scan is set to take 60 seconds, with 10 
seconds between scans. 
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2.5.6. Pulsed EPR spectroscopy 
Pulsed spectra were obtained on a Bruker ElexSys E-580 FT-EPR spectrometer equipped 
with an Oxford Instruments CF935 cryostat. 
HYSCORE used the four-pulse sequence: (π/2)mw – τ – (π/2)mw – t1 – πmw – t2 – (π/2)mw – 
τ – echo. Typically parameters for X-band HYSCORE were: microwave pulse width (π/2)mw = 16 
ns, microwave frequency = 9.62 - 9.71 GHz, magnetic field = 3200 – 3500 G, τ = 128 – 300 ns. The 
time t1 and t2 are incremented in 16, 20 or 24 ns increments for 128 or 256 steps, starting from 80 
ns. Recorded time-domain data undergo baseline correction with a 3rd order polynomial. The 
time-series is then multiplied by a Hamming window function, followed by zero-filling, 2D-
Fourier transformation and symmetrization with the minimum value. 
For ENDOR experiments, a Bruker RF amplifier was used. The following pulse sequences 
were used: 
Mims ENDOR: (π/2)mw – τ – (π/2)mw – πrf – (π/2)mw – τ  – echo. 
Davies ENDOR: πmw – πrf – (π/2)mw – τ – πmw – τ  – echo. 
With (π/2)mw = 16 ns, πrf  = 20 μs for Mims, and (π/2)mw = 48 ns, πrf  = 10 μs for Davies ENDOR 
experiments. For Mims experiment, usually multiple τ values are used and spectra added 
together because of the τ suppression effect for which signal at sin(2πντ) = 0 is suppressed. 
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2.6. Tables and Figures 
 
 
Figure 2.1: Reaction catalyzed by IspG, showing the numbering convention of IspG and IspH 
substrates in this dissertation. 
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Figure 2.2: X-band (9.05 GHz) EPR spectra of IspG in complexes with the reaction intermediate 
and the product HMBPP. Recorded at T = 10 K.  
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Figure 2.3: HYSCORE spectra of “X” formed with IspG and (A) [u-13C5]-MEcPP; (B) [1,3,4-13C3]-
MEcPP; (C) MEcPP 30% 13C enriched at C2 and C3 positions. Spectra are collected at g ~ g2 = 2.018 
with τ = 136 ns, T = 20K. 
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Figure 2.4: HYSCORE spectrum of “X” formed from IspG and MEcPP-epoxide whose epoxide 
oxygen is 17O-labeled. Spectrum was taken at B0 = 341.5 mT, T = 18 K and τ = 136 ns. 
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Figure 2.5: 1H Davies ENDOR of “X” prepared with (A) GcpE + MEcPP. (B) GcpE + MEcPP, in 
D2O buffer. (C) GcpE + [u-2H]-MEcPP. ν = 9.66 GHz; spectra were collected at g2 (B0 = 342.2 mT) 
at T = 20 K. 
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Figure 2.6: ENDOR spectra of “X” generated from deuterated substrates. (A) Mims ENDOR of 
“X” from uniformly deuterated MEcPP; (B) – (E) Mims ENDOR of “X” prepared with [2’-2H3], [1-
2H], [3-2H], [4-2H2] HMBPP epoxides, respectively. (F) Sum of (B) to (E) to show consistency with 
(A). (G) Davies 1H ENDOR spectrum of “X” prepared using [2’-2H3]-HMBPP epoxide (solid line), 
showing the disappearance of the Aiso = 12 MHz 1H signal that was present in “X” prepared from 
non-deuterated MEcPP, indicated by arrows. Spectra were taken at g ~ g2 = 2.018, with ν = 9.76 
GHz; B0 = 345.4 mT; T = 20.0 K. (a-e) are sum spectrum of 30 τ values (from 132 to 1060 ns in 32 
ns steps). 
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Figure 2.7: Proposed IspG organometallic mechanism, with the structure of ferraoxetane 
intermediate “X” shown at (C).  
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Chapter 3. Mechanism of Action of 4Fe-4S Protein IspH 
3.1. Notes and Acknowledgements 
This chapter is partly adapted, with permission, from the following publications: Wang, W. 
et al., 2010. Bioorganometallic mechanism of action, and inhibition, of IspH. Proceedings of the 
National Academy of Sciences, 107(10), pp.4522–4527, Copyright 2010, National Academy of 
Sciences; and Li, J. et al., 2013. Isoprenoid Biosynthesis: Ferraoxetane or Allyl Anion Mechanism 
for IspH Catalysis? Angewandte Chemie, 125(25), pp.6650–6653, Copyright 2013 WILEY-VCH 
Verlag. 
Dr. Weixue Wang performed part of the CW/Pulsed EPR spectroscopy. Dr. Ke Wang 
synthesized most of the isotope-labeled substrates. Prof. Tatyana I. Smirnova provided guidance 
and instrumentation for part of the EPR spectroscopy, and Prof. Yong Zhang and his group 
performed quantum chemical calculations.  
This work was supported by NIH grant (GM065307) to Eric Oldfield, NIH grant 
(GM085774) to Yong Zhang, NSF grant MCB-0843632 to Tatyana I. Smirnova and equipment 
grants from NIH (S10RR023614), NSF (CHE-0840501), and the North Carolina Biotechnology 
Center (NCBC 2009-IDG-1015). I was supported by a pre-doctoral fellowship from the American 
Heart Association, Midwest Affiliate (11PRE7500042) from July 2011 to June 2013. I also thank 
Drs. Hassan Jomaa and Jochen Wiesner for providing the A. aeolicus IspH expression systems, 
and Dr. Mark J. Nilges for assistance with the EPR spectroscopy.  
 
 34 
3.2. Introduction 
Various methods have been attempted to trap reaction intermediates of IspH. An inactive 
E126A (Aeolicus aquifex numbering) mutant facilitates the trapping of a species with g1 ~ 2.12 (54). 
However, under steady-state conditions, a weak signal for another species was observed (55). 
This species also shows a HiPIP-like EPR spectrum, with its g1 ~ 2.17 significantly higher than the 
g1 ~ 2.12 species trapped with E126A mutant. Later, Xu et al (56) reported producing a species by 
using one-electron reduced IspH and removing excessive dithionite reducing reagent. In this way 
a species with an intense EPR signal was trapped with identical g values as the steady-state 
intermediate observed previously. Therefore, efforts are again made to elucidate the structure of 
this reaction intermediate, with the help of isotope-labeled HMBPP and pulsed EPR experiments. 
 
3.3. Results and Discussion  
3.3.1. Proposals of plausible reaction intermediate structure 
There have been a considerable number of proposals of IspH mechanism of action, with 
cationic, anionic, radical, butadiene and organometallic species proposed as intermediates (13–
17, 48, 18). Most of these proposals have been without direct spectroscopic or structural evidence. 
Previous research in the Oldfield Group accumulated considerable evidence in support of the 
organometallic hypothesis (55), in which the intermediate is stabilized by a π interaction between 
the alkene group of HMBPP and the cluster, as shown in Figure 3.1A. Alternatively, a second 
organometallic mechanism was proposed (15) in which a ferraoxetane, similar to previously 
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described for IspG, was the intermediate, as shown in Figure 3.1B, based on CW-EPR and 1H, 2H 
and 31P ENDOR spectroscopy of a newly reported reaction intermediate with g1 ~ 2.17. 
I thus carried out a series of investigation of the chemical nature of this species, with 2H, 13C 
and 17O-labeled substrates and one-electron reduced A. aeolicus IspH. This species is prepared by 
reducing IspH with dithionite, yielding an [Fe4S4]+ cluster, and then removing excess reductant. 
The one-electron reduced IspH was then mixed with HMBPP substrate, and frozen quickly, 
yielding an intense EPR spectrum. The CW-EPR spectrum of this species is shown in Figure 3.2, 
with the HiPIP-like g tensor, gi = [2.17, 2.01, 1.99]. The CW (continuous wave) EPR spectrum was 
essentially the same as the one we reported previously for a sample prepared from wild-type E. 
coli IspH in the presence of excess dithionite and HMBPP under steady-state conditions. 
3.3.2. The absence of 17O hyperfine signal 
I first obtained HYSCORE spectra one-electron reduced IspH (AaIspH) with [1-17O]-
HMBPP (that is, labeled at the 1, CH2OH position in Figure 3.1), since in the IspH ferraoxetane 
model this group is directly bonded to the unique fourth iron in the 4Fe-4S cluster. The HYSCORE 
spectrum obtained using this one-electron reduced sample is shown in Figure 3.3 and, as with 
the E. coli protein under turnover conditions, there is no evidence for any 17O HYSCORE signal. 
Previous work found evidence for a weak (Aiso ~ 1 MHz) 17O hyperfine coupling from the same 
batch of [1-17O]-HMBPP bound to an E. coli IspH E126Q mutant, proposed to be a weak  complex 
(55), but in systems where Fe-O bonds are found, Aiso values are an order of magnitude larger 
(52,53,57).  These results, therefore, do not provide support for the IspH ferraoxetane hypothesis 
but are consistent with formation of an allyl anion complex, in which the 17O has been lost. 
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3.3.3. The 13C HYSCORE spectra, and signal assignment 
Next, I used a uniformly 13C-labeled HMBPP (converted from [u-13C]-MEcPP with GcpE) to 
produce the g1 = 2.17 intermediate species, again with one-electron reduced AaIspH, shown in 
Figure 3.4A. There was no evidence for a large (as large as ~ 17 MHz for the GcpE ferraoxetane 
complex) 13C hyperfine coupling. There were, however, three sets of intermediate-sized hyperfine 
couplings, denoted C(A), C(B) and C(C) in Figure 3.4A, along with possible smaller 13C hyperfine 
signal overlapping with 14N double quantum transition signal. The isotropic hyperfine couplings 
are much smaller than the Aiso (2-13C) ~ 17 MHz reported for the intermediate “X” in IspG.  
To assign these three resonances, Dr. Ke Wang synthesized [1-13C]-, [2-13C]- and [3-13C]-
HMBPPs, and I obtained HYSCORE spectra of the g1 = 2.17 intermediates prepared with them. 
The resultant spectra are shown in Figure 3.4B–D. The sets of signal could unequivocally be 
assigned: C1 to signal C(C), C2 to signal C(A) and C3 to signal C(B). 
3.3.4. Measurement of 13C hyperfine tensors 
The principle values and Euler angles of the hyperfine tensors could be obtained with 
EasySpin simulations (58). To better determine the tensors, HYSCORE spectra of [u-13C]-HMBPP 
+ IspH were acquired at three different g values (or magnetic fields) with two different τ, as 
shown in Figure 3.5. For each specifically-labeled species, simulation was also carried out for two 
different τ values, as shown in Figure 3.6.  
The resultant hyperfine tensors are: 
C1: Aii = [7.3, 0.9, 0.9] MHz, Aiso = 3.0 MHz, α = 15, β = 10, γ = 30. 
C2: Aii = [2.0, 0.5, 6.7] MHz, Aiso = 3.1 MHz, α = 30, β = 50, γ = 80. 
C3: Aii = [-1.1, -0.8, 7.1] MHz, Aiso = 1.8 MHz, α = 0, β = 80, γ = 60. 
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As can be seen, these tensors, although very anisotropic, are quite small compared to the 
tensor obtained with the C-2 of ferraoxetane species we proposed for IspG.  
3.3.5. The 2H HYSCORE spectra 
Next, I investigated the HYSCORE spectra of two 2H-labeled HMBPP molecules, [2-2H3]-
HMBPP and [4-2H2]-HMBPP, bound to IspH to form the g1 = 2.17 reaction intermediate. In 
previous work (55) our group also obtained the HYSCORE spectra of [1-2H2]-HMBPP and [3-2H]-
HMBPP complexed with reduced E. coli IspH (the same g1 = 2.17 reaction intermediate) under 
steady-state conditions. The four HYSCORE spectra are shown in Figure 3.7. In all labeled 
positions, sets of 2H hyperfine signal are seen. Limited by spectral resolution, the small hyperfine 
couplings (< 1 MHz) are not suitable to simulate. But qualitatively they are all smaller than the 
1.7 MHz (2H)/ 12 MHz (1H) spectrum observed with the ferraoxetane species of IspG. What is 
more, although less bonding away from C1 and C2, the methyl (C2‘) deuterons exhibit a smaller 
hyperfine than does the far-away C4 deuterons.  
3.3.6. DFT calculation of hyperfine coupling constants 
To test the consistency of the structural model to the hyperfine tensors, we investigated the 
cluster structure using density functional theory. Dr. Yong Zhang used a [Fe4S4(SMe)3(η3-CH2-
C(CH3)-CH(CH2OH)] cluster, S = 1/2, with Gaussian 09 (revision B.01) (59). After full geometry 
optimization (Figure 3.8), the distances between the unique fourth Fe atom and C1, C2, and C3 
were 2.139, 2.104 and 2.167 Å, respectively. In a previous DFT investigation of the IspG-
ferraoxetane species (51), we established that the calculated isotropic hyperfine coupling to be 
well-correlated with the experimental results by a factor of 1.55. With this correction, the 
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computed Aiso values were in quite good accord with experiment: Aiso (1-13C) = 3.0 MHz (expt.), 
1.91 MHz (calc.); Aiso(2-13C) = 3.1 MHz (expt.), 2.87 MHz (calc.); Aiso (3-13C) = 1.8 MHz (expt.), 1.70 
MHz (calc.), as shown in Figure 3.9 and Table 3.1. 
3.3.7. Conclusion on intermediate structure 
In summary, all the spectroscopy and computational investigation favors the allyl anion 
intermediate (Figure 3.1A) structure over the ferraoxetane structure (Figure 3.1B), for a number 
of reasons: (i) Unlike 17O labeling experiments done with aconitase and IspG, with a [1-17O] 
HMBPP substrate we find no evidence for Fe-O bonding in an IspH reaction intermediate 
prepared by using a one-electron reduced cluster, making a ferraoxetane intermediate unlikely. 
(ii) With the uniformly 13C-labeled HMBPP substrate, we find no evidence for the large (~17 MHz) 
hyperfine interaction seen previously with IspG and attributed there to a ferraoxetane 
intermediate. Rather, we detected three signals, all with hyperfine couplings too small for direct 
Fe-C bonding. Especially, at C2 where the carbon is supposed to bind to iron, the hyperfine 
constant is not significantly greater than C1 and C3. (iii) C1 – C3 hyperfine tensors all contain 
substantial anisotropic terms, suggesting close spatial proximity to the paramagnetic center. With 
a delocalized model such as the allyl anion, the fact of relatively small isotropic terms (and thus 
less Fermi contact interaction or “bonding”) can be reconciled with the close spatial proximity. 
(iv) The large hyperfine coupling on one of the methyl hydrogens found in IspG ferraoxetane 
model is not observed for IspH, although IspG and IspH ferraoxetane models are almost 
symmetric about the methyl group and one should expect similar spectral features from the 
methyl. Besides, with the ferraoxetane model, one would expect the C4 deuteron hyperfine 
coupling to be very small for it is 4 bonds away from the paramagnetic center. However, it 
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showed a hyperfine constant comparable to that of deuterons on C1. (v) The allyl anion model is 
consistent with the formation of both products IPP and DMAPP, because it could be protonated 
at C1 or C3 to form the 1,2- or 2,3- double bond., while for the ferraoxetane model it is difficult to 
account for the formation of DMAPP.  For a clearer picture, the spectroscopic features are drawn 
and compared in Figure 3.10. 
3.3.8. Comparison to X-ray crystallographic results 
Spectroscopic data aside, X-ray crystallography studies provide direct and valuable 
evidence for mechanisms of reaction. However, caveats remains for interpreting crystal 
structures because crystalizing conditions may capture the enzyme-ligand complex in a different 
redox state or different position on the reaction coordinate. Our collaborator Prof. M. Groll’s 
group have crystalized and solved structures of multiple wild-type/mutant IspH-ligand 
complexes (60,61). The question then arises as to whether the g1=2.17 species corresponds to the 
intermediate observed crystallographically. 
While crystal structures give bond lengths and atomic distances directly, hyperfine 
anisotropy provides an estimate of spatial distance between the paramagnetic center and the I ≥ 
½ nucleus. A convenient approximation is to crudely treat the unpaired electron and the 
paramagnetic nuclei both as point magnets, and thus the average distance between them can be 
calculated from the anisotropy part of the hyperfine tensor. In addition, Walsby et al (62) 
improved this method by taking the non-unity spin density at the iron centers into account using 
a spin projection coefficient. Using the spin projection coefficient calculated from aconitases 57Fe 
hyperfine measurements (63), I estimated that the C-Fe distances range from 2.0 ± 0.2 to 2.5 ± 0.2 
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Å for C1-C3. This distance estimate is consistent with the optimized DFT model geometry, but 
shorter than the 2.8 ± 0.3 Å observed in crystal structures (60).  
It was observed by crystallography that the HMBPP alkoxide can bind to the unique fourth 
Fe (PDB 3KE8), but some crystals undergo X-ray radiation for diffraction quality examination 
before data acquirement at synchrotron lost the oxygen density, leaving a planar IPP-like species 
in place (PDB 3KE9). In addition, a structure was obtained with the IspH E126Q mutant with 
HMBPP hydroxyl rotated away from the cluster (although the fourth Fe was lost) and pointed 
towards the mutated E126Q. Therefore it would be conceivable that the C1-C2 bond rotation 
could have taken place along the reaction coordinate.  
Taken together, the presumably best mechanism proposal that reconcile all the 
observations is shown in Figure 3.11, with relevant crystallographic or spectroscopic evidence 
shown for each reaction intermediate step. HMBPP initially binds to the oxidized ([Fe4S4]2+) 
cluster via O-1, as shown by PDB structure 3KE8. Upon cluster reduction, the hydroxyl rotates 
away from the cluster, and the substrate binds to the cluster by forming a weak π-complex, as 
trapped by the E126Q mutant in PDB structure 3SZU. The highly conserved E126 residue 
protonates the hydroxyl and water leaves HMBPP. An internal two-electron transfer occurs from 
the cluster to the substrate, resulting in the allyl anion and the HiPIP-like [Fe4S4]3+ cluster, as 
observed by EPR and HYSCORE spectroscopy. Finally, the cluster is reduced again and a proton 
attaches to either C-1 or C-3, forming the DMAPP and IPP products. 
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3.4. Conclusions 
With one-electron reduced IspH and fast freeze-trapping, we are able to capture the 
paramagnetic intermediate and elucidate its chemical nature. Thanks to Dr. Ke Wang’s isotope-
labeled substrates, assignment of signal was straightforward. The results strongly supports, with 
the corroboration of crystallography data, a route of reaction via a weak π-complex converted to 
a stronger allyl-anion-cluster complex. The result here also lends insight to inhibitor design, as 
will be discussed in Chapter 4. 
 
3.5. Materials and Methods 
3.5.1. Expression, purification and reconstitution of Aquifex aeolicus IspH 
A. aeolicus IspH was transformed into BL-21(DE3) E. coli cells with a pQE-60 plasmid. The 
cells are grown in LB media with 200 mg/L ampicillin at 37 °C until the A600 reached ~ 0.6. Cells 
were then induced with 200 μg/L anhydrotetracycline and grown at 20 °C for 16 h and harvested 
by centrifugation and frozen at -80 °C. 
The purification process is similar to that of T. thermophilus IspG. However, because AaIspH 
does not incorporate iron-sulfur clusters particularly well, even when purified in a glove box, 
cluster reconstitution was performed. Protein was transferred to a room-temperature Coy vinyl 
anaerobic chamber, diluted to ~ 1 mM, and incubated with 20 mM DTT for 1 hour. Then, 0.5 mM 
FeCl3 and 0.5 mM Na2S were slowly added to the protein solution with gentle stirring (~ 60 rpm), 
followed by incubation for 6 – 8 hours. These additions and incubations of FeCl3 and Na2S were 
repeated five times. Care was taken that iron sulfide and protein precipitation were kept to a 
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minimum. The protein solution was then centrifuged at 11,000 rpm for 20 minutes, the 
supernatant concentrated, desalted again (to remove excess metal or sulfide ions), and the 
purified, reconstituted protein was stored in the anaerobic chamber at 4°C. 
3.5.2. Biosynthesis of [u-13C]-HMBPP 
[u-13C]-HMBPP was prepared from [u-13C]-MEcPP. In a Coy anaerobic chamber under 
room temperature, approximately 0.5 mM T. thermophilus GcpE, along with 5 mM sodium 
dithionite and MEcPP was added into a Wilmad screw-cap NMR tube, in a 100 mM ammonium 
bicarbonate buffer (pH ~ 7.8) with 50% D2O, and incubated overnight. The progress of the 
reaction is monitored by 31P NMR spectroscopy. When no significant amount of MEcPP was left, 
the enzyme is removed with a centrifugal concentrator (collecting the filter flow-through instead 
of the retained protein solution). The HMBPP-containing solution is lyophilized, then cation-
exchanged using a DOWEX 50WX8 column pre-equilibrated with NH4+, and then lyophilized 
again before further use. 
3.5.3. EPR spectra simulation 
EPR spectra are usually plotted and analyzed with Matlab (R2011b, The MathWorks, Inc., 
Natick, Massachusetts, United States), and simulate with the EasySpin package. CW-EPR 
spectrum was simulated with the “pepper” function of EasySpin to obtain the principle values of 
the g tensor, which is in turn used to define the system for simulation of pulsed spectrum with 
the “saffron” function.  
Because the parameter space of hyperfine and quadrupole tensors are high-dimensional, it 
is unrealistic to make an exhaustive search for the best tensors. Instead, usually 2 – 3 parameters 
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are varied systematically together, with scripts parallelizing EasySpin threads, and generate 
hundreds to thousands of simulated spectra. The spectra are subjectively compared to the 
experimental spectrum. Parameters are varied interactively and calibrated against multiple 
experimental spectra to get the best tensor fit to experimental data. 
3.5.4. Distance estimate from anisotropic hyperfine coupling 
To obtain an estimate of the actual distances involved, we employed the point dipole 
approximation. The through-space dipolar coupling energy between the unpaired electron and a 
nucleus with a magnetic dipole, and the average distance between them can be estimated by: 
< ݎ >= ቆߤ଴4ߨ ൬
1
ℎܶ൰  ܭ ℎ
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where h is the Planck constant, γe/h and γN/h are the gyromagnetic ratios (in MHz/Tesla) of the 
electron and the nucleus in question, and <r> is the average distance to be estimated. We assumed 
the largest component of the experimental anisotropic hyperfine coupling T (= A – Aiso) (in 
frequency units) tensor to be 2T (in an ideal situation, T will be in the form of [2T, -T, -T], with the 
interaction purely between two point dipoles). K is the spin-projection coefficient used to account 
for non-unity spin density on the relevant iron, which has been reported to range from 0.78 to 
1.86 in the 4Fe-4S cluster protein aconitase, resulting in the lower and upper limits of distance 
estimates.  
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3.6. Tables and Figures 
Table 3.1: Experimental and Calculated Aiso Results. 
Model Atom [a] Expt. Aiso or A (MHz) 
DFT Aiso  
(MHz) 
DFT Aiso/1.55 
(MHz) 
 13C1 3.0 2.96 1.91 
IspH + HMBPP 
allyl anion 
13C2 3.1 4.45 2.87 
 13C3 1.8 2.64 1.70 
 C1-1H1 3.2 0.6 0.4 
 C1-1H2 3.2 0.3 0.2 
 13C2 17.7 38.9 25.1 
 C2-1H1 11.3 9.1 5.9 
 C2-1H2 3.7 2.0 1.3 
IspG + MEcPP 
ferraoxetane C2-1H3 1.3 1.1 0.71 
 13C3 3 0.3 0.2 
 C3-1H 3.2 3.6 2.3 
 C4-1H1 3.2 0.3 0.2 
 C4-1H2 2.0 0.2 0.1 
 17O1 0.15 0.68 0.44 
 17O3 9 11.4 7.4 
[a] Atoms in bold are those of interest here. 
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Figure 3.1: Two competing proposals of the structure of the IspH reaction intermediate.
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Figure 3.2: CW-EPR observation of the intermediate species from wild-type A. aeolicus IspH and 
HMBPP. Spectrum recorded at ν = 9.05 GHz, T = 10 K. 
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Figure 3.3: HYSCORE spectrum of one-electron reduced AaIspH + [1-17O]-HMBPP, sum of 
spectra with  = 128, 182 and 236 ns, B0 = 344.4 mT, T = 10 K. Showing no 17O signal present. 
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Figure 3.4: X-band HYSCORE spectra of one-electron reduced AaIspH + 13C-labeled HMBPPs. (A) 
[u-13C]-labeled HMBPP, sum spectrum of  = 128, 150, 166, 182, 196 and 208 ns, B0 = 344.7 mT, ν 
= 9.68 GHz. (B) – (D) Specifically-labeled HMBPP. Spectra are sum with   = 136, 160 and 196 ns, 
B0 = 344.1 mT, ν = 9.69 GHz. All spectra were recorded at T = 10 K.  
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Figure 3.5: Experimental and simulated HYSCORE spectra of one-electron reduced AaIspH + [U-
13C5]-HMBPP. Left column are experimental spectra at 10K. Right column are the spectral 
simulations. (A,B) 9.68 GHz, B0 = 344.7 mT,  = 166 ns. (C,D) 9.68 GHz, B0 = 344.7 mT,  = 208 ns. 
(E,F) 9.68 GHz, B0 = 347.4 mT,  = 166 ns. (G,H) 9.68 GHz, B0 = 347.4 mT,  = 196 ns. (I,J) 9.69 GHz, 
B0 = 335.7 mT,  = 160 ns. (K,L) 9.69 GHz, B0 = 335.7 mT,  = 200 ns. 
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Figure 3.5 (cont.) 
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Figure 3.6: Experimental and simulated 9.69 GHz HYSCORE spectra of one-electron reduced 
AaIspH + specifically 13C-labeled HMBPPs. Left column are experimental spectra at 10K. Right 
column are simulations. (A,B) + [1-13C]-HMBPP,  = 136 ns. (C,D) + [1-13C]-HMBPP, B0 = 344.1 mT, 
 = 196 ns. (E,F) + [2-13C]-HMBPP,  = 136 ns. (G,H) + [2-13C]-HMBPP, B0 = 344.1 mT,  = 196 ns. (I,J) 
+ [3-13C]-HMBPP, B0 = 344.1 mT,  = 136 ns. (K,L) + [3-13C]-HMBPP,  = 196 ns. All spectra were 
taken at 10 K and B0 = 344.1 mT. 
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Figure 3.6 (cont.) 
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Figure 3.7: (A) 9.68 GHz HYSCORE spectrum of EcIspH + racemic [1-2H]-HMBPP under turnover 
condition, τ = 136 ns, T = 15 K, g = 2.010. (B) Same conditions as (A), but with [3-2H]-HMBPP. (C) 
9.68 GHz HYSCORE spectrum of one-electron reduced AaIspH + [2-2H3]-HMBPP, τ = 200 ns, T = 
10 K, g = 2.009, B0 = 344.2 mT. (D) Same conditions as (C) but with [4-2H2]-HMBPP. 
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Figure 3.8: Geometrically optimized model of the [Fe4S4]+ cluster + allyl anion. 
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Figure 3.9: Zero-intercept linear regression of model DFT calculations versus experimental Aiso 
data for IspG ferraoxetane (blue) and the IspH allyl anion model (red) reaction intermediates.  
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Figure 3.10: Hyperfine couplings (Aiso, MHz) observed for reaction intermediates in IspH and 
IspG catalysis based on HYSCORE and/or ENDOR spectra with isotopically-labeled substrates. 
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Figure 3.11: Proposed reaction mechanism for IspH, based on crystallography and spectroscopy 
data. 
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Chapter 4. Diverse Inhibitor Binding Modes of IspH 
4.1. Notes and Acknowledgements 
This chapter is partly adapted, with permission, from the following publications: Wang, W., 
Li, J., Wang, K., Smirnova, T.I., Oldfield, E., 2011. Pyridine Inhibitor Binding to the 4Fe-4S Protein 
A. aeolicus IspH (LytB): A HYSCORE Investigation. J. Am. Chem. Soc. 133, 6525–6528. Copyright 
2011, American Chemical Society; and Guerra, F., Wang, K., Li, J., Wang, W., Liu, Y.-L., Amin, S., 
Oldfield, E., 2014. Inhibition of the 4Fe–4S proteins IspG and IspH: an EPR, ENDOR and 
HYSCORE investigation. Chem. Sci. 5, 1642–1649. Copyright 2014, Royal Society of Chemistry. 
Dr. Weixue Wang and Francisco Guerra performed a large part of the CW/Pulsed EPR 
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from July 2011 to June 2013. I also thank Drs. Hassan Jomaa and Jochen Wiesner for providing 
the A. aeolicus IspH expression system, Dr. Deb Berthold (Rienstra Lab) for guidance on 15N-
labeled protein expression, and Dr. Mark J. Nilges for assistance with the EPR spectroscopy. 
NCSA/Terigrid provided computational resources for the pyridine inhibitor study. 
 
4.2. Introduction 
The MEP pathway is present in most bacteria as well as in the protozoan parasite, 
Plasmodium falciparum, the causative agent of the most common and serious form of malaria (3,64). 
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This pathway is essential for survival for many pathogens, while not present in humans. In 
addition, the MEP pathway is present in plants, making inhibitors of interest as potential 
herbicides. The discovery of organometallic species as reaction intermediates, as discussed in the 
previous chapters, facilitates the design of new inhibitors. Many moderately potent inhibitors (~ 
μM level) of IspH have been discovered, with some of them potent against IspG as well. In 
general, three classes of inhibitors have been reported: alkyne pyrophosphates, pyridine 
pyrophosphates and HMBPP analogs. Spectroscopy, crystallography and computational 
chemistry all facilitated the understanding of the binding of these inhibitors to IspH. In this 
chapter, I will focus the discussion on the binding of pyridine and HMBPP analogs to IspH. 
 
4.3. Results and Discussion  
4.3.1. π/σ-complexes in IspH mechanism and inhibition 
Synthetic 4Fe-4S clusters have been shown to form complexes with alkynes and even 
aromatic species (65–67). The formation of η2- or η3- alkenyl species, or π/σ metallacycle by IspG 
and IspH has been noticed in the context of both reaction mechanism and inhibition (68,54). 
HMBPP in complex with the IspH E126 mutant is characterized by weak π-interaction based on 
the HYSCORE/ENDOR observations of small 17O hyperfine coupling (55) and moderate (A ~ 1-2 
MHz) 13C hyperfine coupling (Figure 4.1).  
Knowledge from the weak and strong π/σ-complexes discussed in the IspH reaction 
mechanism gave inspiration for rational design for inhibitors that form such complexes. It has 
been confirmed that alkyne species, such as propiolic acid and propargyl pyrophosphate (69), 
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also bind to IspH, causing significant spectroscopic change as evidenced by EPR (Figure 4.2). 
Propargyl pyrophosphate has been found as an IspH inhibitor, with Ki = 0.97 μM. Upon binding, 
it is typical that the alkyne species cause the EPR spectrum to become HiPIP-like, similar as the 
binding of the HMBPP substrate. Propargyl pyrophosphate is also found to be a potent IspG 
inhibitor, with Ki ~ 330 nM. 
The discovery of alkyne inhibitors has been useful for the design and understanding of 
other species as IspH inhibitors. 
4.3.2. Pyridine inhibitors: spectroscopic observations 
With a screening of a group of compounds previously available in the Oldfield Lab, 
pyridine bisphosphonates are found to be mild inhibitors of IspH activity. Considering that the 
branched nature of the bisphosphonate group might be a hindrance for binding, the synthetic 
chemists in our lab prepared analogs containing pyrophosphate groups (shown in Figure 4.3). 
Better inhibitors were discovered, with the most potent two having IC50s of 38 μM and 9.1 μM, 
labeled 1 and 2 in Figure 4.3.  
Both inhibitors are pyridines substituted at the meta-position. Adding one CH2 spacer to 
the simplest molecule 1 gave the better inhibition activity of compound 2. However, further 
addition to the length of side chain, or making the substitution at different positions of the 
pyridine ring, caused diminishing inhibition activity. Chlorination on the pyridine ring also gave 
much weaker inhibition.  
We thus sought to understand the binding modes of the pyridine inhibitors to the IspH 
protein. Initially, it was conceived that given the essentiality of E126 residue in IspH catalysis, 1 
and 2, while anchored by the pyrophosphate group, could be protonated and the pyridinium 
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forming a salt bridge to E126 carboxylate (Figure 4.4C), simply blocking the substrate from access 
to the iron-sulfur cluster instead of having a direct interaction with it, based on computational 
docking results. However, is this binding mode true, and can direct evidence from spectroscopy 
support it? We next conducted a series of experiments and computational studies to answer the 
question. 
We first investigated a series of pyridine ligands binding to wild-type IspH from A. aeolicus. 
The results are shown in Figures 4.5 (for 1) and 4.6 (for others). It appeared that intense 14N 
HYSCORE signal is positively correlated with inhibition. On addition of the inhibitor 1, the EPR 
spectrum changes (Figure 4.6A) and new signals attributable to 14N single- and double-quantum 
transitions appear in the (+, −) quadrant of the HYSCORE spectrum (Figure 4.5A). By contrast, 
there was no evidence for any sizable pyridine-14N hyperfine interaction in the HYSCORE 
spectrum (Figure 4.6B), indicating only very weak binding affinity to IspH. The same results are 
obtained with the more basic (pKa = 6.8 vs 5.2) species 2-aminopyridine (Figure 4.6C).  
The ortho- and para-pyridyl analogues of 1 (IC50 = 1.2 mM and 149 μM) show no evidence 
of any sizable pyridine-14N hyperfine interaction in their HYSCORE spectra (Figure 4.6D, E), due 
presumably to their inability to bind to the fourth Fe, for “steric” reasons. Moreover, chlorine 
substitution of 1 results in loss of all activity (IC50 > 3 mM), due presumably to loss in donor ability 
of the pyridine nitrogen (the computed pKa values of the pyridine fragments in 1 and 6-chloro-1 
are 4.7 and 0.7, respectively), consistent with the absence of a pyridine-14N HYSCORE signal 
(Figure 4.6F). Addition of one CH2 group to the side chain of 1 results in a better inhibitor (2, IC50 
= 9.1 μM), although there is no significant difference between the HYSCORE spectra of 1 (Figure 
4.5A) and 2 (Figure 4.6G), indicating that differences in enzyme inhibition are due to differences 
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in the alkyl diphosphate fragment binding in the active site, rather than differences in Fe-pyridine 
interactions. 
The 14N hyperfine interaction is quite large, with the hyperfine coupling constant being 8 
MHz. Simulation of the HYSCORE spectrum yielded Aiso(14N) = 7.4 MHz, Aii(14N) = [6.2, 7.6, 8.4] 
MHz for the hyperfine interaction, and e2qQ/h = 3.0 MHz for the nuclear quadrupole coupling 
constant.  
These results do not, however, definitively prove that the 14N HYSCORE signals in the (+, 
−) quadrant arise directly from the inhibitors 1 and 2 because, in principle, inhibitor binding might 
result in a protein conformational change and binding of a protein ligand to Fe, e.g., the nearby 
His 42 or 124, which form part of the active site (18). To investigate this possibility, we prepared 
a sample using uniformly 15N-labeled IspH and inhibitor 1. As can be seen in Figure 4.5B, the 14N 
signals centered at 3.6 MHz seen in Figure 4.5A are no longer present and are replaced by a 
signal centered at 1.5 MHz, the 15N Larmor frequency. Moreover, the 14N signals in the (+, −) 
quadrant are essentially identical to those seen in samples prepared using unlabeled IspH. This 
strongly suggests that the signals centered at 3.6 MHz arise from protein 14N near the 4Fe-4S 
cluster, while the 14N signals in the (+, −) quadrant arise from the bound inhibitor 1, rather than 
from any protein residues. 
4.3.3. Pyridine inhibitors: computational investigation for binding modes 
This large Aiso(14N) is similar to, or even larger than, those of a number of systems in which 
nitrogens directly bind to Fe centers, for example, in met-myoglobin the porphyrin nitrogens (70),  
in the Rieske-type 2Fe-2S proteins (71),  and in the case of the 4Fe-4S enzyme MoaA (a SAM-
dependent enzyme which also has an unique fourth iron) (72). On average, these previous results 
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gave an Aiso(14N) ~ 6 MHz for systems containing Fe−N bonds, suggesting that the IspH + 1 
complex also contains an Fe−N bond. 
The large 14N hyperfine interaction seen in the IspH + 7 complex might also, at least in 
principle, indicate that the pyridine fragment is just close to the reduced 4Fe-4S cluster, without 
directly bonding to the fourth iron. For example, the pyridine group might be protonated and 
interact with the E126 carboxylate group that is close to the cluster, or it could be close by but 
deprotonated. Fortunately, determination of the 14N nuclear quadrupole coupling constant 
(e2qQ/h) enables an answer to this question, since protonated, neutral, and metal-coordinated 
pyridine ligands have very different e2qQ/h values (73). 
For pyridine itself, e2qQ/h = 4.6 MHz, but in species in which there is a formal 1+ charge on 
N, such as the pyridinium ion, pyridine-N-oxide, and N-methylpyridinium, e2qQ/h values of 
approximately 1 MHz are observed experimentally. For pyridine complexes with N-metal bonds, 
in  the case pyridine bonded to Fe in Fe(CO)4(pyr), e2qQ/h is in between these extreme values 
(e2qQ/h ≈ 2.4 MHz), and for Mo(pyr)2(CO)4 and Cr(CO)4(2,2′-bipyridyl), e2qQ/h ≈ 3.1 MHz. So, 
when pyridine N is bonded to Cr, Mo, or Fe, the e2qQ/h decreases from the 4.6 MHz seen in free 
pyridine to 2.4 − 3.1 MHz, due to metal-ligand bonding, close to the 3.0 MHz value we find from 
the 14N HYSCORE results. 
To see to what extent these e2qQ/h values might be reproduced computationally, we used 
the Gaussian 09 program to calculate the 14N nuclear quadrupole coupling constant (NQCC) 
values for a series of pyridine, imidazole or triazole complexes, as shown in Figure 4.7. Results 
are shown in Table 3.1, with 4 different functional/basis sets combinations attempted. All four 
model chemistries gave reasonably well correlation between theory and experiment (Figure 4.8).  
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We also performed the same set of NQCC calculation for a model of IspH + 1, a simple 
[Fe4S4(SMe)3(η1-pyr)] compound (Figure 4.9). A full geometrical optimization yielded the head-
on η1 complex with N-Fe distance of 1.95 Å. NQCC calculation finds e2qQ/h = 2.3 for the pyridine 
14N, in quite good accord with experiment. 
This large decrease in e2qQ/h, from the 4.6 MHz value found for free pyridine to the 2.4 - 3.1 
MHz values observed in model systems and the IspH + 1 complex, is also seen in proteins in 
which imidazole (histidine) ligands bind to Fe. For example, for imidazole, the N3 (deprotonated) 
e2qQ/h is 4.032 MHz, in good accord with the 3.894 MHz computed using DFT. The e2qQ/h values 
for solid imidazole and solid histidine are both smaller and essentially identical (3.27 MHz for 
imidazole; 3.36 MHz for histidine), due presumably to very strong hydrogen bonding in the solid 
state. But when imidazole and histidine are bound to Fe in metalloproteins, e2qQ/h decreases 
considerably from the 4 MHz gas-phase value (for imidazole). 
These results all support the idea that the IspH pyridine inhibitors bind to IspH via a Lewis 
acid/base (Fe4S4 cluster/ligand) mechanism, with the donor orbital occupancy (σ) decreasing from 
2 (pyridine) to 1.73 (73), and that the hyperfine coupling seen experimentally is due to this η1-
bonding, rather than being due to a neutral pyridine or pyridinium ligand just being close to the 
4Fe-4S cluster. This, in turn, suggests that stronger Lewis bases (such as imidazole-containing 
ligands) may be more potent IspH inhibitors. These results also support the idea that other 
inhibitors, such as alkynes, as well as reaction intermediates (η3-allyls), also act as Lewis bases 
when interacting with the 4Fe-4S cluster in IspH. 
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4.3.4. Amine and thiol analogs of HMBPP 
More recently, the amine (3) and thiol (4) analogs of HMBPP have been reported (74) to be 
even more potent IspH inhibitors (IC50 ~ 0.2 μM) and it was shown via Mössbauer spectroscopy 
and quantum chemical calculations that both bound to the oxidized ([Fe4S4]2+) form of IspH, 
forming Fe-N and Fe-S bonds, respectively, with the fourth Fe. We have found that, like the 
acetylene inhibitors, they are also IspG inhibitors, with IC50 values ranging from 0.8 to 2.5 μM 
(75). The structures of 3 and 4 are shown in Figure 4.10. Moreover, we also performed EPR and 
HYSCORE investigations into the nature of the inhibition of both IspH by 3 and 4, in the presence 
of reductant.  
We began by investigating binding of the amine ligand 3 to A. aeolicus, Plasmodium 
falciparum, and E. coli IspHs. The 9.05 GHz EPR spectrum at 10K of dithionite-reduced, 
unliganded AaIspH was reported previously to be a mixture of an S = 1/2 and S = 3/2 species(15), 
with the S = 1/2 species having gi = [2.041, 1.919, 1.849], Figure 4.11A. In the presence of 3, intense 
and sharp signals with gi = [2.138, 2.005, 1.978] (for AaIspH) are seen (Figure 4.11A-D), suggesting 
that the ligand binds at or close to the [Fe4S4]+ cluster in all three IspHs.  
Two main possibility of 3 binding to IspH exists: (i) 3 binds via its NH2 group to the [Fe4S4]+ 
cluster in basically the same manner as proposed for binding to the oxidized cluster, forming a 
Fe-N bond to the fourth Fe.  (ii) 3 might bind to IspH with its aminomethyl group “rotated-out”, 
away from the cluster, interacting with E126, as discussed earlier for the CH2OH group in the 
HMBPP substrate, as seen crystallographically and as confirmed by 17O-HYSCORE spectroscopy 
results in the previous chapter. 
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To help distinguish between these two possibilities, we acquired the HYSCORE spectra of 
3 bound to AaIspH, Figure 4.12A, as well as to EcIspH, Figure 4.13. To distinguish any 14N 
hyperfine interaction with the protein backbone from that with the ligand 3, we also obtained the 
HYSCORE spectrum of 3 bound to 15N-labeled AaIspH, Figure 4.12B.  
If there were a Fe-N bond present in the complex, we would expect a sizeable 14N hyperfine 
coupling since there would be a strong metal-ligand orbital overlap facilitating spin density 
transfer from the metal to the ligand. For example, with the pyridine inhibitor 1 and 2 bound to 
IspH, the 14N hyperfine interaction Aiso (14N) is 7.4 MHz, and on average ~ 6 MHz for species 
containing Fe-N bonds. In addition, the gi = [2.138, 2.005, 1.978] tensor principle values for EcIspH 
+ 3 are essentially very close to those we find with HMBPP bound to EcIspH E126A mutants, gi = 
[2.132, 2.003, 1.972]. We thus conclude that there is no direct Fe-N bond in the reduced IspH + 3 
complex when the cluster is reduced, rather, 3 most likely binds to reduced IspH in basically the 
same manner as does HMBPP  in the “rotated-out” HMBPP X-ray structure (60). A model is built 
with HMBPP ligand’s OH group is replaced by an NH3+ group, shown in Figure 4.13.  As can be 
seen in this (X-ray based) structural model, the ligand’s CH2NH3+ group can interact with the 
E126 carboxylate, providing strong Coulombic interactions that may help account for its potent 
IspH inhibition under reducing conditions. 
Interestingly, there is a small feature centered close to (-1.5, 1.5) MHz in both AaIspH + 3, 
and EcIspH + 3 spectra that has not been seen previously with any other ligands. It did not change 
when 15N-labeled AaIspH protein was used instead of natural abundance AaIspH (Figure 4.12B), 
so it does not arise from a 14N hyperfine coupling with the protein backbone. The feature can be 
simulated with a 14N hyperfine interaction having Ai = [1.85, 1.25, 3.70] MHz, Aiso = 2.33 MHz, 
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e2qQ/h = 0.8 MHz, η = 0.2 (Figure 4.14). The quadrupole coupling constant is consistent with that 
expected for an alkyl ammonium group, e2qQ/h ~ 0 – 1 MHz (76), and the hyperfine coupling 
anisotropy suggests close proximity to the paramagnetic center, consistent again with the 
“rotated-out” model. 
We next investigated binding of the thiol ligand 4, to EcIspH.  It is reported that the IC50 
values for 3 and 4 in inhibiting EcIspH are very similar and both bind to the oxidized protein, 
forming Fe-N and Fe-S bonds respectively with the fourth Fe in the cluster (74). However, the 
electronic structure of the complex with 4 is spin-delocalized while that with 3 is spin-localized, 
suggesting that there might be significant differences in electronic structure between 3 and 4 
when bound to reduced IspH.  
 The EPR spectrum of AaIspH in the presence of sodium dithionite is shown in Figure 4.15A 
(blue) and is characteristically broad, as is the case without the substrate. However, essentially 
no signal is seen in the g ~ 2 region (or at lower field, Figure 4.15A inset) for a sample incubated 
with dithionite in the presence of the thiol ligand 4 (Figure 4.15A, red), unlike the situation with 
3.  This suggested to us the possibility that in the presence of the thiol ligand, the cluster might 
not be reduced, remaining in the S = 0 state.  
This appears to be the case, as corroborated by the UV-Vis spectra shown in Figure 4.15B. 
The spectrum of oxidized ([Fe4S4]2+) AaIspH (blue) shows a characteristic peak at ~ 420 nm, which 
disappears on dithionite reduction (green).  The spectrum of oxidized IspH + 4 (red) is similar to 
that of the oxidized protein in the absence of 4; however, addition of dithionite minimally changes 
the spectrum; the shoulder at ~ 420 nm is still seen with IspH + 4 + dithionite.  We also find that 
addition of 4 to dithionite-reduced IspH regenerates the 420 nm shoulder (superimposed on the 
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large dithionite background peak), suggesting that reduced IspH + 4 is relatively unstable, 
consistent with the lack of any EPR signal for this system. 
 
4.4. Conclusions 
Overall, the results presented here exhibit a surprising variety of binding behavior of IspH 
inhibitors. Acetylenes, like HMBPP, bind to the cluster side-on forming a π/σ-complex. Pyridine 
derivatives 1 and 2, by contrast, form a strong Fe-N bond with a large hyperfine coupling 
constant. The amide HMBPP analog, 3, while forming a Fe-N bond with the unique fourth Fe of 
the [Fe4S4]2+ cluster, seems to rotate the NH2/NH3+ group away and bind to E126 via Coulombic 
interactions, evidenced by the absence of large 14N hyperfine interaction. Most unexpectedly, the 
binding of the thiol HMBPP analog, 4, appears to alter the redox properties of the clusters, and is 
not reduced by dithionite. This diversity in spectroscopic behavior, and hence binding modes are 
of obvious interest for drug design targeting isoprenoid biosynthesis.  
Very recently, a crystallographic study of the IspH-pyridine inhibitor complex revealed 
that the fourth iron binds to the pyridine via a N and a C atoms in a side-on η2 manner (77). With 
quantum chemical calculations on model systems, the 14N isotropic hyperfine and quadrupole 
coupling constants predicted are consistent with that obtained from spectroscopy. Again the 
binding mode mimics the π-complex seen with the substrate/intermediate binding to IspH. 
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4.5. Materials and Methods 
4.5.1. 15N-labeled A. aeolicus IspH expression and purification. 
 To express 15N-labeled protein, the Chapter 3 protocol for AaIspH was modified. Aside 
from LB medium, M9 minimal medium is also prepared, without the 14N nitrogen source, but 
supplemented with 4 g/L glucose, 1 g/L [15N2]-(NH4)2SO4 (Cambridge Isotope Labs), 1% (v/v) 
MEM vitamin solution (Sigma-Aldrich), 0.5% (v/v) 15N-labeled BioExpress cell growth medium 
(Cambridge Isotope Labs), 0.2 mM trisodium citrate, and 0.1 mM FeCl3. In addition, 2 – 20 μM 
trace element supplements including CaCl2, MnCl2, ZnSO4, CoCl2, CuCl2, NiCl2, Na2MoO4, 
Na2SeO3 and H3BO3 were added through a .22μM filter, according to the protocol provided in Ref 
(78). Usually iron-sulfur proteins are also expressed in medium supplemented with L-cysteine, 
but for effective incorporation of 15N into amino acids, this step is omitted. 
 BL-21(DE3) cells were grown at 37∘C aerobically in 1 L of LB medium first, until OD600 
reached ~ 1.4. The cells are spun down with gentle centrifugation at 20 ∘C, 5000 rpm for 10 
minutes. The cells are re-suspended in PBS, and transferred to M9 + supplement medium 
described above, and protein expression was induced at 25 °C with anhydrotetracycline. Cells 
were harvested 20 hours after. 15N-labeled AaIspH protein was then purified and reconstituted as 
described in Chapter 3. 
4.5.2. IspH inhibition assay 
The inhibition assay was performed in a room-temperature anaerobic chamber with O2 
level < 1 ppm, and all buffers and solvents were degassed with a vacuum manifold and stirred in 
the anaerobic chamber for > 12 hours.  
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The assay mixture (200 μL on a 96-well plate) contains 40 nM IspH, 34 μM HMBPP, 2 mM 
methylviologen and 0.3 mM sodium dithionite in a 50 mM Tris/HCl, 100 mM NaCl, pH 8.0 buffer. 
The IspH enzyme was incubated with or without inhibitor. Reaction were started by addition of 
the HMBPP substrates, and monitored by decrease in OD600. 
4.5.3. IC50 determination 
The IC50, half maximal inhibitory concentration, is defined as the concentration of inhibitor 
needed for inhibiting half of the enzyme activity. For different inhibitor concentration [I], the 
reaction rate for a competitive inhibitor is  
ݎ =  ௠ܸ௔௫ܭ௠[ܵ] ൬1 + ൬
[ܫ]
ܭ௜ ൰
௣
൰ + 1
 
where Vmax is the reaction rate at infinite inhibitor concentration without any inhibitors, Km is the 
Michaelis-Menten constant, and Ki is the association constant of the inhibitor to the enzyme. Only 
the latter of these constants are related to the inhibitor, while all others are intrinsic kinetic 
properties of the enzyme. Therefore, given a fixed substrate [S] in an assay, the IC50 can be 
expressed as  
ܫܥହ଴ =  ܭ௜(1 + [ܵ]/ܭ௠) 
which is proportional to Ki, which in turn is the constant that characterizes the inhibitor’s binding 
efficiency to the enzyme. 
For each inhibitor of interest, different concentrations (usually a serial 2x – 4x dilution is 
made) of the inhibitor (from mM to nM, depending on the efficiency of the inhibitor) was 
incubated with the enzyme, and the rates were plotted against inhibitor concentrations. The curve 
is fitted in Origin Pro to the following dose-response curve. 
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ݎ = ଴ܸ + ଵܸ
− ଴ܸ
1 + exp (−݌(log[ܫ] − log ܫܥହ଴) ) 
Where r is determined from linear regression of first few minutes of the time trace of OD600 
obtained from a spectrophotometer. Pairs of (r, log[I]) are the data points and  V0, V1, p and IC50 
are the parameters to be estimated with non-linear curve fitting. 
4.5.4. Quantum chemical calculations of 14N NQCC 
All QM calculations were performed with Gaussian 09 software. For all systems, geometry 
optimization was carried out using the BPW91 functional, a Wachters+f (79,80)  basis set for first-
row transition metals, 6-311+G* (81)  for other atoms.  The optimized structures were then used 
to calculate the 14N nuclear quadrupole coupling constants using BPW91 (82,83) or B3LYP  (84,85) 
functionals, and the aforementioned Wachters/6-311+G* or TZVP (86) basis sets. There was small 
difference between the calculated NQCC results.  
The quadrupole coupling of 14N nucleus is just the product of its quadrupole and the electric 
field gradient at the position of the nucleus (the nucleus is very small compared to the atom, so it 
is valid to consider it as a point). The QM calculations gave electric field gradient (eq) in atomic 
units; a conversion factor eQ/h = 4.8027 MHz/a.u (with the nuclear quadrupole Q = 0.02044 barn, 
1 barn = 10-28 m2) for 14N was used to calculate the energy e2Qq/h value in MHz to fit 
spectroscopists’ convention. 
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4.6 Tables and Figures 
Table 4.1:  Calculated 14N nuclear quadrupole couplings of 15 model compounds using four different basis set/functional combinations. 
Molecule 
Experiment BPW91/TZVP BPW91/Wachters B3LYP/TZVP B3LYP/Wachters 
e2qQ/h η e2qQ/h η e2qQ/h η e2qQ/h η e2qQ/h η 
Pyridine 4.584[a] 0.396[a] 4.727 0.369 4.686 0.326 4.944 0.364 4.990 0.410 
Pyridinium (HSO4-) 1.197[a] 0.426[a] 1.105 0.211 1.262 0.109 1.070 0.206 1.247 0.098 
Imidazole(N) 4.032[b] 0.120[b] 3.894 0.050 3.825 0.002 4.160 0.108 4.081 0.055 
Imidazole(NH) 2.537[b] 0.178[b] 2.655 0.177 2.778 0.218 2.696 0.165 2.831 0.209 
1,2,4-Triazole(N1H) 2.95[b] 0.553[b] 3.021 0.462 3.133 0.417 3.068 0.477 3.195 0.425 
1,2,4-Triazole(N2) 4.41[b] 0.728[b] 4.288 0.74 4.201 0.794 4.535 0.683 4.438 0.739 
1,2,4-Triazole(N4) 4.01[b] 0.102[b] 3.843 0.052 3.781 0.001 4.065 0.087 3.995 0.033 
Pyridine oxide 1.227[a] 0.426[a] 1.126 0.159 1.185 0.004 0.875 0.826 0.942 0.535 
Pyridine sulfur trioxide 1.52[c] 0.15[c] 1.876 0.078 1.856 0.047 1.940 0.138 1.923 0.002 
N-methylpyridinium 0.545[a] 0.07[a] 1.105 0.211 1.262 0.109 1.070 0.206 1.247 0.098 
Fe(CO)4Py 2.402[a] 0.319[a] 2.246 0.232 2.271 0.139 2.755 0.299 2.780 0.212 
Cr(CO)4(2,2'-biPy) 3.124[a] 0.237[a] 2.843 0.094 2.871 0.026 3.307 0.203 3.341 0.137 
mitoNEET cluster His 2.47[d] 0.38[d] 2.800 0.223 2.746 0.299 3.196 0.104 3.160 0.188 
Rieske cluster His 1 2.6[e] 0.346[e] 2.610 0.315 2.639 0.355 2.999 0.162 3.022 0.233 
Rieske cluster His 2 2.3[e] 0.391[e] 2.570 0.272 2.603 0.375 2.953 0.186 2.978 0.254 
IspH + inhibitor 1 3.0 0.2 2.268 0.530 2.363 0.534 2.571 0.160 2.877 0.331 
 
Sources for experimental data: [a]. Reference (73).  [b]. Reference (87).  [c]. Reference (88).  [d]. Reference (89).  [e]. Reference (90).  
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Figure 4.1: Difference Davies ENDOR spectra of isotope-labeled HMBPP binding to IspH E126A 
mutant. (A) 2H region spectra with natural abundance spectra subtracted, showing only 2H. The 
31P region is unsubtracted ENDOR result. (B) 13C region of [u-13C]-HMBPP complex, with natural 
abundance spectra subtracted. Adapted from Ref (54), with permission.  
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Figure 4.2: 9 GHz EPR spectra of IspH at 15 K, reduced with dithionite. (A) A. aeolicus IspH, no 
added ligands. (B) E. coli IspH, no added ligands. (C) A. aeolicus IspH + KCN. (D) A. aeolicus IspH 
+ propiolic acid. (E) A. aeolicus IspH + but-3-ynyl diphosphate. Spectral simulations are shown by 
the dashed lines. Adapted from Ref. (69), with permission, Copyright 2010, American Chemical 
Society.  
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Figure 4.3: Potential pyridine inhibitors and their IC50s. 
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Figure 4.4: Initially proposed binding modes of IspH ligands. (A) π (or π/σ)-metallacycle complex 
formation by alkyne inhibitors. (B) IspH catalysis in which an η2-alkenyl metallacycle is reduced 
and protonated and then dehydrates to form the allyl anion complex. (C) IspH inhibition by 
pyridinium diphosphates which block HMBPP binding to the fourth Fe.  
  
 77 
 
Figure 4.5: HYSCORE spectrum of the pyridine inhibitor, 1, in complex with A. aeolicus IspH (A) 
with natural-abundance IspH and (B) with 15N-labeled IspH. 
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Figure 4.6: X-band (A) CW-EPR of IspH + compound 1 and (B)-(G) HYSCORE of IspH + other 
pyridine ligands. 
 79 
 
Figure 4.7: Model compounds used for calculation of 14N nuclear quadrupole coupling. 
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Figure 4.8: Correlation between experimental and computed e2qQ/h values, using four different 
basis set/functional combinations. 
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Figure 4.9: Geometry optimized model of [Fe4S4] cluster-pyridine complex. 
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Figure 4.10: Amine (3) and thiol (4) analogs of HMBPP serving as IspG/H inhibitors. 
  
 83 
 
Figure 4.11: X-band CW-EPR spectra of IspH reduced with dithionite, (A) with or (B)-(D) without 
the inhibitor 3. Green line shows simulation.  
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Figure 4.12: HYSCORE spectra of IspH with nitrogen-containing inhibitor 3. (A) AaIspH + 3.  T = 
15 K, ν = 9.706 GHz, B0 = 3455 G, sum spectrum of  = 136, 168, 200 and 256 ns. (B) 15N-labeled 
AaIspH + 3.  T = 15 K, ν = 9.712 GHz, B0 = 3460 G, sum spectrum of  = 136, 168, 200 and 256 ns.   
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Figure 4.13: Model for binding of 3 (protonated, ammonium form) based on the X-ray structure 
of IspH + HMBPP, based on PDB ID 3KE8 and 3SZU, Ref. (60).  
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Figure 4.14:  Experimental and simulated HYSCORE spectra of amino-HMBPP (3) + EcIspH.  
Experimental condition: B0 = 3440 G, ν = 9.665 GHz with (A)   = 136 ns. (B)  = 172 ns. (C) τ = 208 
ns. (D) τ = 244 ns.  Simulation parameters: Ai = [1.85, 1.25, 3.70] MHz, α = 0∘, β = 22∘, γ = 20∘, e2qQ/h 
= 0.8 MHz, η = 0.2.  
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Figure 4.15: 9.05 GHz CW-EPR and UV-Vis spectra of AaIspH + 4.  (A) CW-EPR spectra of 1.3 
mM AaIspH + 20 eq dithionite (blue) and 1.3 mM AaIspH + 20 eq dithionite + 10 eq 4 (red). T = 
10K, power = 2 mW. Inset: CW-EPR spectra of the same two samples with extended magnetic 
field range (500 G – 5500 G). (B) UV-Vis spectra of AaIspH oxidized (blue); reduced (green); + 4 
(cyan); + 4 + dithionite (red). 0.05mM AaIspH, 50 eq dithionite, 50 eq 4. UV-Vis spectra taken in 
an anaerobic environment (O2 < 2 ppm) at 25 °C.  
 88 
Chapter 5. Preliminary Study of Mechanism of 4Fe-4S Protein 
Quinolinate Synthase 
5.1. Notes and Acknowledgements 
This work was supported by NIH grant (GM065307) to Eric Oldfield, I was supported by a 
pre-doctoral fellowship from the American Heart Association, Midwest Affiliate (11PRE7500042) 
from July 2011 to June 2013. I thank Prof. James Imlay for the NadB plasmid, Prof. Dennis Dean 
for providing the isc plasmids for iron-sulfur cluster generation, and Dr. Mark J. Nilges for 
assistance with the EPR spectroscopy. 
 
5.2. Introduction 
This chapter is a foray into the unfamiliar territory, beyond the context of isoprenoid 
biosynthesis. NadA catalyzes the key step of the formation of a pyridine ring, and like the other 
pyridine ring formation enzyme 3-hydroxyanthranilate 3,4-dioxygenase (91) of the tryptophan 
pathway, it requires iron centers to perform its function. It is a 4Fe-4S cluster-containing protein, 
with a unique fourth iron and a trefoil overall structure also seen with other 4Fe-4S proteins such 
as IspH and the radical SAM protein Dph2 (92). 
The mechanism of NadA has remained elusive, partly because the many reaction steps are 
relatively independent and the sequence of events along the reaction coordinate is difficult to 
determine (Figure 5.1), as is the role of the 4Fe-4S cluster. Here, I present our preliminary results 
on research into the mechanism of NadA, with bioinformatics and spectroscopic methods. 
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5.3. Results and Discussion  
5.3.1. Homology modeling and conserved residues 
The crystal structure of NadA containing an intact 4Fe-4S cluster was reported only very 
recently (21). Before it became available, we used the Phyre 2 server (93) to build a homology 
model for the E. coli NadA protein we worked with, based on previously reported structures 
without the cluster (20), shown in Figure 5.2. 
I used the Jpred server (94) to generate a multi-sequence alignment of NadA homologs, and 
with the SCORECONS server (95), residues in this alignment were scored and ranked. Apart from 
aliphatic amino acids and cysteines, the top 7 conserved residues are listed in Table 5.1. When 
located on the homology model as well as the crystal structure, they naturally cluster into two 
“green” and “red” domains, and all of them are close to the iron-sulfur cluster in the crystal 
structure. The next highest-ranked residue, K147, appeared to form a salt bridge with E93, both 
highly conserved but far away from the center where the cluster resides. 
5.3.2. Site-directed mutagenesis 
Next, I performed site-direct mutagenesis for the top 7 conserved residues and attempted 
expression and purification of 9 mutants, as listed in Table 5.2. For these mutants, 4 of them did 
not show the dark brown color typically associated with iron-sulfur proteins, and all these 4 
precipitated soon after elution from the Ni-NTA column. The other 5 seemed to harbor the iron-
sulfur cluster, but unsurprisingly for top conserved residues, their mutants are all inactive, as 
judged by an NMR activity assay. 
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5.3.3. HYSCORE investigation of ligand binding 
It was determined by Mössbauer spectroscopy that anaerobically purified E. coli NadA 
cluster is in the [Fe4S4]2+ redox state (17). It has also been shown that NadA is also active under 
reductive conditions (26) by HPLC, and our own NMR experiment confirm this activity in the 
presence of dithionite. Therefore, it is interesting to see how the cluster, when reduced, binds to 
substrates, product, and other ligands, through CW and pulsed EPR spectroscopy.  
We thus prepared EPR samples of E. coli NadA with quinolinate (product), DHAP + 
iminoaspartate (substrates), and a known inhibitor, phosphoglycolohydroxamate (PGH). The 
HYSCORE spectra are shown in Figure 5.3. However, even though the ligands contained nitrogen 
and phosphate atoms, we could not observe any large 14N or 31P hyperfine coupling. This indicates 
that, when the cluster is reduced, the N atoms on iminoaspartate, quinolinate and PGH are far 
away from the cluster, as are the P atoms in DHAP and PGH. 
5.3.4. HYSCORE investigation of a purported reaction intermediate 
The recently published crystal structure of T. maritama NadA does not contain a ligand 
other than water (21). However, the authors proposed a “last-step” intermediate, 5-hydroxyl-4,5-
dihydroquinolinate (Figure 5.4A), with the 5-OH group binding to the unique fourth Fe, based 
on computational docking. I thus set out to investigate whether this intermediate can be observed 
with the reduced protein by HYSCORE. 
As found with NMR, if the NadA reaction is carried out in D2O, 5-H of the final product 
will be deuterated. Therefore, if the intermediate binds to the reduced cluster, in D2O, one will 
likely observe a large D hyperfine for 5-D, because it is only two bonds away from the iron and 
presumably also very close spatially. In addition, the authors also proposed E228 serves as the 
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final relay of proton abstraction from the intermediate. Presumably, an E228 mutant would arrest 
the reaction at this stage and raise the concentration of this intermediate. Therefore, we prepared 
3 samples in 85% D2O for HYSCORE investigation: WT protein without the substrates, WT 
protein plus substrates, and E228D mutant protein plus substrates. 
The HYSCORE results are shown in Figure 5.4B-D. Rather disappointingly, all spectra only 
showed one intense 2H hyperfine signal at the deuteron Larmor frequency with very small Aiso, 
most likely from deuteron exchanged into the protein.  
 
5.4. Conclusions 
The HYSCORE results reported here so far have been mostly negative results rather than 
positive evidence for iron-sulfur cluster-ligand binding. There could be several possible reasons: 
(i) The protein is not stoichiometrically reduced by dithionite, and the [Fe4S4]2+ species remaining 
unreduced is active rather than the reduced [Fe4S4]+-IspH, which can bind the ligands without 
involvement of the cluster. (ii) The reduced cluster binds to the ligands via the carboxylate 
groups, like observed in aconitase (96), rather than the 5-OH. (iii) The reaction goes through 
another mechanism for which the E228D mutant fails to trap the intermediate. Taken together, 
with these preliminary results, the reaction mechanism or structure of intermediate-protein 
complexes still remains elusive, and further research should be warranted. 
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5.5. Materials and Methods 
5.5.1. E. coli NadA expression and purification 
E. coli NadA gene was cloned into a pET46 Ek/Lic vector. The plasmid bearing the gene was 
co- transformed with a pDB1282 plasmid into BL-21(DE3) E. coli cells. Cells were grown in LB 
medium with 100 mg/L ampicillin and 50 mg/L kanamycin at 37 ∘C. 1 g/L L-arabinose was added 
to induce the isc gene expression when OD600 reached 0.3, along with 0.2 mM FeCl3 and 0.1 g L-
cysteine. 0.5 mM IPTG was added when OD600 reached 0.8. The incubation was continued for 16 
hours at 20 ∘C, and then the cells were harvested by centrifugation. Cell pellets were re-
suspended in buffer A (50 mM HEPES/KOH and 100 mM KCl, 10 mM imidazole, pH 7.5),  lysed 
by sonication and then centrifuged at 24,000 rpm at 4 °C for 20 min. The supernatant was loaded 
onto a HisPur Ni-NTA spin column equilibrated with a buffer A. After washing with 2x column 
volume buffer A for three times, protein was eluted with 2x column volume of buffer B (same as 
buffer A, but containing 250 mM imidazole) three times. Dark-brown colored fractions 
(confirmed to contain AaIspH by SDS-PAGE) were collected, pooled, concentrated and then 
desalted on a PD-10 column with an imidazole-free buffer (50 mM HEPES/KOH and 100 mM 
KCl, pH 7.5) to remove imidazole. Furthermore, the buffer was exchanged with a 40% glycerol 
buffer with the same pH and salts with an Amicon filter, and the protein was stored at -80 ∘C 
before use. Because NadA is not very stable at room temperature and incorporate Fe-S clusters 
reasonably well, no further reconstitution was performed. For D2O EPR samples, protein are 
exchanged into a D2O + 100 mM NH4HCO3 buffer and 20% pure glycerol was added. 
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5.5.2. Site-directed mutagenesis 
Site-directed mutagenesis was carried out with the QuikChange II Site-Directed 
Mutagenesis Kit (Agilent). The primer used are synthesized by Integrated DNA Technologies: 
Y139A:  5'-atcgtactgtcgtcgtcgccgccaacacttctgctg-3’ 
5'-cagcagaagtgttggcggcgacgacgacagtacgat-3' 
N141A: 5'-gtcgtcgtctacgccgccacttctgctgcggt-3' 
  5'-accgcagcagaagtggcggcgtagacgacgac-3' 
T155A:  5'-acggcaatgcttgaagctaccacccaatctgcg-3'  
  5'-cgcagattgggtggtagcttcaagcattgccgt-3' 
D178E:  5'-gccccagatgtttctcgggtgcccaga-3' 
5'-tctgggcacccgagaaacatctggggc-3' 
D178N:  5'-gccccagatgtttgttgggtgcccagatgat-3'  
5'-atcatctgggcacccaacaaacatctggggc-3'  
H203A: 5'-ctgagtcttaaattcatcagccacaatacaggcaccctgc-3'  
  5'-gcagggtgcctgtattgtggctgatgaatttaagactcag-3'   
H226A: 5'-gcttgtggtgattctggagccaccagtatggcagcatc-3'  
5'-gatgctgccatactggtggctccagaatcaccacaagc-3' 
E228D: 5'-gcttgtggtgaatctggatgcaccagtatggca-3' 
  5'-tgccatactggtgcatccagattcaccacaagc-3' 
E228Q: 5'-caatagcttgtggtgactgtggatgcaccagtatggcagc-3'  
  5'-gctgccatactggtgcatccacagtcaccacaagctattg-3' 
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5.5.3. NMR NadA activity test 
The activity of WT and mutant enzymes were tested by NMR. Typical reaction mixture 
contains 10% D2O, 100 mM (NH4)HCO3, 10 mM DHAP and either (i) 10 mM oxaloacetic acid (to 
produce iminoaspartate with NH4+) or (ii) 10 mM L-aspartate, 15 mM fumarate, 0.01 mM FAD 
and 0.1 mM E. coli NadB. It should be noted that when dithionite is present, (ii) cannot be used 
because FAD will be reduced. After incubation of 20 – 40 min with enzyme, quinolinate 
production can be detected by observing the 3 aromatic 1H signal on NMR, as reported previously 
(97), with 1H NMR (500 MHz, D2O) δ: 7.38 (H-5, 1H, m), and 7.90 (H-6, 1H, d), 8.24 (H-4, 1H, d).
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5.6. Tables and Figures 
Table 5.1: Top 7 conserved residues from SCORECONS results. 
Score 
E. coli 
residue # Residue 
0.984 178 D 
0.971 203 H 
0.971 226 H 
0.969 155 T 
0.967 228 E 
0.966 139 Y 
0.966 141 N 
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Table 5.2: Results of site-directed mutagenesis of top conserved residues. 
Mutant Stability Color Activity 
Y139A Stable Brown No 
N141A Stable Brown No 
T155A Stable Brown No 
D178E Unstable Clear N/A 
D178N Unstable Clear N/A 
H203A Unstable Clear N/A 
H226A Unstable Clear N/A 
E228D Stable Brown No 
E228Q Stable Brown No 
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Figure 5.1: Possible reaction mechanisms of NadA. 
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Figure 5.2: (A) Homology model of E. coli NadA. (B) Crystal structure of Thermotoga maritama 
NadA with an intact 4Fe-4S cluster. Green: H203, H226 and E228. Red: Y139, N141, T155 and 
D178. Yellow: cluster ligand cysteins C113, C200 and C297. 
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Figure 5.3: X-band HYSCORE spectra of reduced EcNadA (A) + quinolinate, τ = 136 ns; (B) + 
DHAP and iminoaspartate, τ = 200 ns; (C) + phosphoglycolohydroxamate, τ = 136 ns. All spectra 
were acquired at ν = 9.75 GHz, B0 = 360.9 mT, T = 10 K. 
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Figure 5.4: (A) Purported last-step reaction intermediate by Ref. (21). And HYSCORE spectra of 
(B) WT protein in D2O without addition ligands; (B) WT protein in D2O plus substrates; and (C) 
E228D mutant in D2O plus substrates. All spectra were taken at ν = 9.66 GHz, B0 = 357.6 mT, and 
T = 10 K. 
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Chapter 6. Lipophilic Bisphosphonates Targeting Squalene 
Synthase and Farnesyl Pyrophosphate Synthase 
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6.2. Introduction 
The study described in this chapter is conducted in the context of neglected tropical diseases 
research, against trypanosomatid parasites. For example, Chagas disease, caused by the 
protozoan parasite Trypanosoma cruzi, affects eight million individuals (98), primarily in Latin 
America. Ergosterol is the essential membrane sterol in many trypanosomatid parasites like T. 
cruzi and plays the same structural role as cholesterol does in humans. Therefore, there is 
currently considerable interest in inhibiting endogenous sterol biosynthesis as a route to the 
development of novel anti-infective drugs.  
A prominent example of such inhibitors is bisphosphonates (Figure 6.1), originally 
established as treatment to human bone resorption diseases (99) with human farnesyl 
pyrophosphate synthase (FPPS) as the target. They were found to inhibit the enzyme FPPS and 
active against T. cruzi (100,101). Nitrogen containing bisphosphonates (Figure 6.1A) are thought 
to mimic the cationic transition state or reaction intermediate of FPPS with the positively charged 
N group, while the bisphosphonate group mimics the diphosphate group of natural 
substrates/products (102,103).  
More recently, lipophilic bisphosphonates (Figure 6.1B), analogs of zoledronate and 
risedronate, has been shown to target other enzymes such as geranylgeranyl pyrophosphate 
synthase (GGPPS) (104) in addition to FPPS, and the FPPS/GGPPS dual-function enzyme in 
malarial parasites (105,106). Curiously, in these studies the best activity against FPPS/GGPPS 
were found with short-to-medium size side chains, while the activity against malaria parasite 
almost monotonically increase with larger side chains.  
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In this chapter, I report that besides FPPS, squalene synthase (SQS) is also targeted by these 
lipophilic bisphosphonates. We explored the relationship between the side chain size and its 
inhibition activity against FPPS, SQS, as well as in cells. In addition, our discovery of lipophilic 
bisphosphonates as SQS inhibitors also facilitated new crystallographic endeavors that have 
revealed interesting binding phenomenon. 
 
6.3. Results and Discussion  
6.3.1. Two series of lipophilic bisphosphonates, derivative of zoledronate 
Dr. Yonghui Zhang and Dr. Ke Wang prepared two series of analogs of one small 
bisphosphonate, zoledronate.  One series is synthesized by varying the group attached to the N3 
of the imidazole ring, with an n-alkyl group, from H up to C15H31.  
The other series has the same substitution, and additionally the 1-hydroxyl group from the 
zoledronate “base molecule” was replaced with a hydrogen. The rationale for the removal of -
OH group is that, as reported previously, bisphosphonates bind to bone mineral, which involves 
the interaction of the phosphonate groups, the 1-OH group, as well as of an unhindered cationic 
side-chain with the bone surface (107).  
For a shorthand, each compound was assigned an internal number in the lab, and are 
abbreviated as Cn-OH and Cn-H series, n ranging from 0 to 15. 
6.3.2. Lipophilic bisphosphonates are indeed potent SQS inhibitors 
Suspecting SQS might be a target of lipophilic bisphosphonates in T. cruzi,  we initially 
attempted to accelerate the measurement of IC50s of the two series of lipophilic bisphosphonates 
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against T. cruzi SQS with an assay continuously monitoring the release of pyrophosphate (108). 
As a result, such an assay yielded results showing very modest inhibition, Figure 6.3. The best 
inhibitor has an IC50 of 550 nM.  
However, the pyrophosphate release assay is an indirect measurement, not monitoring the 
formation of squalene but that of a side product that is released in both steps of the reaction, and 
its low sensitivity requires a high concentration (450 μM) of substrates, nearly 90 times of the 
reported Km (5.2 μM) of the enzyme (109). To avoid these complications, we used a more 
established end-point assay, which directly measures the amount of [3H]-labeled FPP substrate 
incorporated into the final product, squalene, by scintillation counting (109). Both series of 
bisphosphonates were tested against T. cruzi and human SQS (Figure 6.4).  
In addition, T. cruzi FPPS inhibition were also tested (Figure 6.5), and plotted along with 
previously obtained HsSQS inhibition results (106). All assay results are also tabulated in Table 
6.1. 
As seen in Figure 6.4, short side-chain bisphosphonates exhibit very little SQS inhibition. 
For medium to long side-chains, there is an increase in potency with increasing chain length up 
to n = 10 or 11, but then potency decreases on further chain elongation. There is no obvious effect 
of the 1-OH/1-H group on enzyme inhibition. 
By contrast, the increase in activity against FPPS (both species) with chain length is less 
pronounced, and maximum activity is found with a C6 – C8 substituent. When the side chain 
elongates beyond C10, the activity drastically decreases (Figure 6.5), unlike the more moderate 
decrease found with SQS.  
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6.3.3. Parasite growth inhibition, rescue and ergosterol synthesis inhibition 
Our collaborator Roberto Docampo also tested a subset of these bisphosphonates for their 
ability to inhibit the proliferation of the clinically relevant amastigote form of T. cruzi, with results 
shown in Figure 6.6.Activity in T. cruzi cell growth inhibition increases almost monotonically with 
increasing chain length up to the longest C14 – C15 side-chain species investigated (Figure 6.6). 
This could be presumably attributed to enhanced cell permeability, similar to the case of 
FPPS/GGPPS bisphosphonate inhibitors in Plasmodium (106). 
Rescue experiments were performed in the presence of the C10-H species, no rescue was 
afforded by farnesol, and only ~ 20% rescue by geranylgeranyl. Sterol biosynthesis analysis was 
also performed in the presence of the C10-H species at 4 μM, with ergosterol components 
analyzed by GC/MS, LC/MS and LC/UV. The content of exogeneously-acquired cholesterol in T. 
cruzi epimastigotes increased from 51% to 71% of total sterols, while that of endogenous 
ergosterol decreased from 36% to 15% of total sterols. 
6.3.4. Crystal structures of lipophilic bisophosphonates bound to SQS 
Previous crystallography efforts of SQS/CrtM have identified two substrate binding sites 
(38), the allylic binding site S1, where FPP or the substrate analog FSPP bind to a cluster of highly 
conserved aspartate residues via Mg2+, and a homoallylic binding site S2 which binds to the 
FPP(FSPP) diphosphate group via basic residues. 
We next sent the C10/C15 species, with or without the hydroxyl, to Dr. Rey-Ting Guo’s lab 
for crystal structure determination. Two T. cruzi SQS structures (with C10-OH and C15-H) and 
four human SQS structures were successfully determined. With the FSPP structures 
superimposed to serve as a guide to the S1 and S2 sites, the newly solved structures are shown in 
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Figure 6.7. Basically, the S2 farnesyl-binding site was occupied by the n-alkyl side chains. For the 
shorter, C10 inhibitor species, the site S2 is occupied. For the C15 species, the 8 distal side-chain 
carbons occupy the S2 site, but the side-chain then bends and occupies the S1 site, before bending 
back with the bisphosphonate head group returning to the S2 site. 
 
6.4. Conclusions 
Summarizing the enzyme inhibition, parasite growth inhibition/rescue and sterol 
biosynthesis inhibition results, we can conclude that, for the most effective long side-chain 
lipophilic bisphosphonates, FPPS was not likely a major target, although inhibition of ergosterol 
biosynthesis is indeed targeted. Instead, SQS was highly likely the target. The most T. cruzi 
amastigote growth inhibition was achieved with the long side-chain (C14-15) inhibitors, which, 
although not the best SQS inhibitor, are still highly-potent and with its effects balanced by 
enhanced hydrophobicity and better cell penetration. In addition, our inhibition studies 
facilitated determination of new crystal structures showing interesting binding modes, which will 
also be of great interest in future development of SQS inhibitors as anti-infective drug leads. 
 
6.5. Materials and Methods 
6.5.1. SQS expression and purification 
Both TcSQS and HsSQS were expressed according to previously established protocols 
(109,110). Briefly, pET-28a plasmids bearing truncated but functional and His-tagged TcSQS and 
HsSQS were transformed into BL-21 (DE3) cells. Cells are grown at 37 ∘C in LB medium with 50 
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mg/L kanamycin. Incubation was continued until OD600 reached 0.6-0.8. Then 1 mM IPTG was 
added and incubation continued for 4 hours. Cells were harvested by centrifugation (9000 rpm, 
15 minutes), and frozen at -80 ∘C before use. 
The proteins were purified using HisPur Ni-NTA spin columns. Cell pellets were 
suspended in 15 mL buffer A (50 mM HEPES/KOH, pH 7.5, and 100 mM NaCl), and sonicated 
for 5 minutes in 5 second pulses. The suspension was centrifuged (24000 rpm, 20 minutes), and 
the supernatant was loaded onto the column pre-equilibrated with 96% buffer A + 4% buffer B 
(same as buffer A, but with 250 mM imidazole) by gravity flow. The spin column was washed 
three times with 2x column volume of 96% buffer A + 4% buffer B, and then His-tagged protein 
was eluted three times with 100% buffer B. Both proteins were desalted with buffer A on PD-10 
columns, concentrated, and frozen at -80 ∘C in buffer A + 20% glycerol before use. 
6.5.2. T. cruzi FPPS expression and purification 
T. cruzi FPPS was basically purified with previously reported protocols (111).  DNA coding 
for an N-terminal tag and a thrombin cleavage site was attached to the TcFPPS gene and 
cloned in to a pET28a vector, transformed BL-21(DE3) E. coli cells. Cells are grown and harvested 
the same way as SQS. 
To purify the protein, the cells were re-suspended in 20 mL (per 1 L of cell growth 
medium) of buffer A (50 mM phosphate buffer, 500 mM NaCl, 10 mM imidazole, 2 mM tris(2-
carboxyethyl)phosphine (TCEP), final pH 8.0), placed on ice, and broken with sonication. 
The sonicated suspension was centrifuged (24000 rpm for 20 minutes), and the supernatant was 
loaded onto a Ni-NTA column pre-equilibrated with buffer A on an AKTA Prime FPLC system. 
The column was washed with buffer A until no more protein was washed down the column 
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(judged by O D280 of the flow-through < 0.06). The protein was then eluted with a gradient 
of 0 – 100% of buffer B (same as buffer A, but with 250 mM imidazole). The 42 kDa FPPS 
containing fractions (judged by OD280 and SDS-PAGE) were pooled and concentrated with an 
Amicon filter. 10 units of thrombin was added to the mixture and incubated at 4 ∘C overnight 
to cut off the His-tag. The completion of the cleavage was confirmed by native PAGE.  The 
mixture was then l oaded onto a benzamidine column to remove the thrombin, and a Ni-NTA 
column to remove His-tag peptide. The flow-through containing TcFPPS was pooled and 
dialyzed 3 times against 1 liter of buffer C (20 mM Tris/HCl, 50 mM NaCl and 2 mM TCEP) and 
concentrated. The purified protein (judged by SDS-PAGE and native-PAGE) were stored in -80 
∘C until use. 
6.5.3. SQS inhibition assay 
Initially, SQS enzyme inhibition assays were carried out, in duplicate, in 96-well plates, 
with a total of 200 μL of reaction mixture in each well. Reactions were monitored by using a 
continuous spectrophotometric assay for phosphate releasing enzymes, in a buffer contained 50 
mM Tris-HCl pH 7.4, 1 mM MgCl2, 250 μM NADPH, and 450 μM FPP. The compounds 
investigated were pre-incubated with 2 μg of SQS for 30 min at 20 °C. 
After the initial assay we used a radioactivity assay with 3H-labelled FPP substrate. The 
reaction mixture (50 μL) had 2.5 nM T. cruzi or H. sapiens SQS, 0.5 μM [1-3H]-FPP, and 250 μM 
NADPH, in a detergent-containing buffer (50 mM HEPES-KOH, pH 7.5, 100 mM NaCl, 4 mM 
MgCl2, 0.5% Tween 80, 2 mM CHAPS, and 4 mM DTT). The enzymes were incubated with 
inhibitor for 10 minutes before addition of the substrates. The reaction was allowed to continue 
at 37 ∘C for 15 minutes and then terminated with 50 μL of 0.1 M NaOH/methanol. The product 
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was extracted with 500 μL of hexanes and 300 μL of the organic layer was measured by 
scintillation counting. 
6.5.4. FPPS inhibition assay 
For FPPS inhibition, the condensation of geranyl diphosphate (100 μM) and IPP (100 μM) 
was monitored at room temperature by using a continuous spectrophotometric assay for 
phosphate. The reaction buffer contained 50 mM Tris-HCl, pH 7.4, 1 mM MgCl2, and 0.01 % Triton 
X100. The compounds investigated were pre-incubated with enzyme for 30 min at room 
temperature.  
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6.6. Tables and Figures 
Table 6.1: IC50 values (in μM) for lipophilic bisphosphonates inhibiting T. cruzi/human SQS and 
FPPS, and T. cruzi amastigote cell growth. Results are average of 2 or 3 measurements. 
Structure TcSQS HsSQSTcFPPSHsFPPST. cruzi Amastigotes 
C-0,OH > 10 > 10 0.16 0.10 >10 
C-1,OH > 10 > 10 0.22 0.080 >10 
C-2,OH > 10 > 10 0.11 0.049 >10 
C-3,OH > 10 > 10 0.33 0.034 >10 
C-4,OH > 10 > 10 0.37 0.030 >10 
C-5,OH > 10 > 10 0.18 0.049 >10 
C-6,OH 3.1 3.0 0.12 0.044 >10 
C-7,OH 0.37 0.68 0.09 0.040 >10 
C-8,OH 0.11 0.27 0.15 0.036 9.3±1.8 
C-9,OH 0.021 0.075 0.22 0.080 7.0±1.0 
C-10,OH 0.018 0.089 0.13 0.23 3.5±0.3 
C-11,OH 0.030 0.11 0.55 0.21 6.4±1.1 
C-12,OH 0.046 0.13 0.74 0.49 Not determined 
C-13,OH 0.064 0.18 1.07 4.2 1.2±0.3 
C-14,OH 0.12 0.24 > 5 42 1.2±0.1 
C-15,OH 0.10 0.27 > 5 60 3.0±1.0 
C-0,H > 10 > 10 0.26 0.14 > 10 
C-1,H > 10 > 10 0.37 0.19 > 10 
C-2,H > 10 > 10 0.31 0.08 > 10 
C-3,H > 10 > 10 0.39 0.066 > 10 
C-4,H > 10 > 10 0.39 0.079 > 10 
C-5,H > 10 > 10 0.35 0.11 > 10 
C-6,H 2.0 2.7 0.09 0.058 > 10 
C-7,H 0.21 0.72 0.12 0.044 > 10 
C-8,H 0.06 0.21 0.16 0.040 > 10 
C-9,H 0.016 0.10 0.085 0.043 10 ±2 
C-10,H 0.017 0.053 0.30 0.10 3.1 ± 0.6 
C-11,H 0.010 0.11 0.39 0.28 4.0 ±1.3 
C-12,H 0.052 0.14 0.90 0.37 1.1 ±0.4 
C-13,H 0.058 0.22 0.91 0.35 1.1 ±0.1 
C-14,H 0.12 0.29 > 5 3.0 0.8 ±0.3 
C-15,H 0.14 0.26 > 5 8.3 1.0±0.1 
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Figure 6.1: Chemical structures of examples of bisphosphonates. (A) “Conventional” 
bisphosphonates. (B) Lipophilic bisphosphonates. 
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Figure 6.2: Zoledronic acid and its derivatives involved in this research. 
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Figure 6.3: T. cruzi SQS inhibition versus side chain length by two series of lipophilic 
bisphosphonates, measured by the pyrophosphate release assay.  
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Figure 6.4: T. cruzi and human SQS inhibition versus side chain length by two series of lipophilic 
bisphosphonates, measured by the radioactive squalene extraction assay. 
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Figure 6.5: T. cruzi and human FPPS inhibition versus side chain length by lipophilic 
bisphosphonates.  
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Figure 6.6: T. cruzi amastigote cell growth inhibition versus side chain length by two series of 
lipophilic bisphosphonates. 
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Figure 6.7: Crystal structures obtained with T. cruzi and human SQS with lipophilic 
bisphosphonates. FSPP-SQS structures were superimposed on the new structures to show the S1 
and S2 FPP binding sites. 
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